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A patient with metastatic BRAF-mutated colorectal cancer initially responded to combined EGFR 
and BRAF inhibition with panitumumab plus vemurafenib. Pre-existing cells with increased MET 
gene copy number in the archival tumor tissue likely underwent clonal expansion during treatment, 
leading to the emergence of MET amplification in the re-biopsy taken at progression. In BRAF-
mutated colorectal cancer cells, ectopic expression of MET conferred resistance to panitumumab and 
vemurafenib, which was overcome by combining BRAF and MET inhibition. Based on tumor 
genotyping and functional in vitro data, the patient was treated with the dual ALK-MET inhibitor 
crizotinib plus vemurafenib, thus switching to dual MET and BRAF blockade, with rapid and marked 
effectiveness of such strategy. Although acquired resistance is a major limitation to the clinical 
efficacy of anticancer agents, the identification of molecular targets emerging during the first 
treatment may afford the opportunity to design the next-line of targeted therapies, maximizing patient 
benefit. 
Statement of significance 
MET amplification is here identified – clinically and pre-clinically - as a new mechanism of 
resistance to EGFR and BRAF dual/triple block combinations in BRAF-mutated colorectal cancer. 
Switching from EGFR to MET inhibition, while maintaining BRAF inhibition, resulted in clinical 
benefit after the occurrence of MET-driven acquired resistance.   
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Introduction 
Anticancer targeted therapies are hardly ever curative. Even in the setting of precision medicine, 
targeted agents fail to achieve prolonged responses in the vast majority of cases. Molecular 
characterization of tumor samples taken at relapse can inform about the mechanisms underlying 
acquired drug resistance and drive subsequent lines of therapy with the ultimate goal of prolonging 
disease control. 
Combinations of anti-EGFR monoclonal antibodies and BRAF inhibitors (BRAFi), with or without 
other agents such as MEK or PI3K inhibitors, are emerging as an effective strategy to target BRAF 
V600E mutated metastatic colorectal cancer (CRC) (1-6). Therefore, BRAF mutations are evolving 
from a poor prognostic biomarker and a negative predictive factor for single-agents anti-EGFRs or 
BRAFi (7,8), to a positive selection marker for BRAFi-based dual or triple combinations. 
Nevertheless, the long-term efficacy of these targeted combinations is limited by the relatively rapid 
emergence of drug resistance (1, 2). Scant data are available about the molecular mechanisms 
underlying acquired resistance to targeted agents combinations in CRC. A previous study including 
three patients reported that acquired resistance to BRAFi in combination with either EGFR or MEK 
blockade in CRC cell lines and/or clinical samples is caused by the emergence of MAPK pathway 
molecular alterations including amplification of KRAS or mutated BRAF V600E, or mutations in 
KRAS or MAP2K1 (9). However, the identification of the above mentioned molecular mechanisms 
has had no or very limited impact on the clinical management of individual BRAF mutant patients. In 
this work, we present how defining the spectrum of resistance mechanisms is critical to develop 
optimal subsequent treatment strategies aimed at prolonging survival. By genotyping a tissue biopsy, 
we identified the emergence of MET gene amplification as a mechanism of acquired drug resistance 
in a BRAF mutated metastatic CRC patient initially treated with the combination of panitumumab 
and vemurafenib. We describe how the combined data obtained by tumor molecular profiling and 
functional experiments in cell lines assisted therapeutic decision-making and offered the opportunity 




Emergence of MET gene amplification upon acquired resistance to panitumumab and 
vemurafenib  
The patient clinical history is summarized in Figure 1. Approximately two years after multimodality 
treatment for BRAF V600E mutated, microsatellite stable mucinous rectal cancer, a 48-year-old man 
was diagnosed with pelvic relapse and liver metastases. First-line therapy with FOLFOXIRI obtained 
a disease stabilization lasting 9 months, indicating that intensive triplet treatment may achieve best 
outcomes in the poor-prognosis BRAF mutant mCRC patient subset. Following liver disease 
progression, the patient was given off-label treatment with panitumumab and vemurafenib according 
to a previously published phase II study (5). Within days of treatment start the patient symptoms 
improved and, after 2 months, a CT scan showed a partial response according to RECIST version 1.1 
criteria (Figure 2). Unfortunately, after 4 months, disease progression occurred (Figure 2). At this 
time, a liver tumor biopsy was obtained in order to investigate molecular mechanisms of acquired 
drug resistance. Molecular analyses were carried out in parallel both in pre-treatment primary tumor 
tissue and in post-treatment liver biopsy. Amplicon-based next-generation sequencing (NGS) of 
selected exons in 110 genes (Supplementary Table S1) did not identify nucleotide variants previously 
implicated in resistance to EGFR monoclonal antibodies or BRAF target therapies. In details, this 
analysis ruled out secondary mutations in likely candidate resistance genes including EGFR, KRAS, 
NRAS or MAP2K1.  
 
Since amplicon-based NGS approaches do not allow accurate assessment of gene copy number 
changes, we performed immunohistochemical and in situ hybridization (ISH) analyses of HER2 and 
MET, as the activation of these genes had previously been associated with acquired resistance to 
EGFR monoclonal antibodies in CRC (10,11). No changes in HER2 expression or gene copy number 
status were observed (Supplementary Table S2). However, a marked difference was seen in MET 
expression (Figure 2). Analysis of the archival rectal sample showed heterogeneous MET 
immunostaining, with a strong membrane signal in about 50% neoplastic cells (H-score: 150), while 
the remaining cell population showed a weak to moderate membranous staining. Heterogeneity was 
also observed in MET gene copy number. By ISH (FISH and SISH) analyses, we estimated that the 
signals corresponding to the MET and CEP7 (chromosome seven α-centromeric) probes ranged from 
1 to 8 (mean values of 3.52 and 2.89 for MET and CEP7, respectively), with a gene-to-chromosome 
ratio of 1.2, indicating chromosome 7 polysomy. However, in a small fraction of cells within the pre-
treatment sample, the gene-to-chromosome ratio was ≥6, indicating subclonal MET gene 
 6 
amplification (Figure 2, Supplementary Table S2). In the post-progression liver biopsy, MET was 
strongly expressed at the membrane level in about 90% neoplastic cells (H-score: 270). In this 
sample, MET copy number varied from 1 to 30 (mean 8.5), while CEP7 ranged from 1 to 16 (mean 
3.24) with an overall gene-to-chromosome ratio of 2.62. At least 75% cells in the liver biopsy were 
found to carry MET gene amplification (Figure 2, Supplementary Table S2) (defined by a gene-to-
chromosome ratio ≥6), indicating that dual EGFR-BRAF blockade had positively selected for MET 
amplified clones.  
Since MDM2 gene amplification has frequently been found to co-occur with  MET genetic alteration 
in lung cancer (12), we assessed MDM2 gene copy number by ISH. This analysis suggested that dual 
BRAF and EGFR treatment had selected for MDM2-coamplified clones (Supplementary Figure S1, 
Panels A-B). 
In order to investigate the prevalence of MET amplification in the context of BRAF mutant CRC,  we 
performed MET ISH analysis on archival tumor tissue of 17 BRAF V600E advanced CRC samples. 
Three out of 17tumors (18%) from chemonaïve  patients displayed MET amplified subclones 
(Supplementary Figure S2, Panels A-D ).  
Overexpression or amplification of MET confers resistance to targeted therapy combinations in 
BRAF mutant CRC cell lines 
In order to assess whether MET overexpression alone is causally responsible for resistance to 
combinatorial vemurafenib and panitumumab treatment, we conducted in vitro forward genetic 
experiments. We took advantage of the BRAF mutant colorectal cancer cell line WiDr, which we had 
previously shown to be refractory to either single agent BRAF or EGFR inhibitors, but sensitive to 
their combination (13). Ectopic overexpression of MET in WiDr parental cells was able to confer 
resistance to combined vemurafenib and panitumumab by activating ERK signaling (Figure 3A) and 
sustaining proliferation (Figure 3B). Importantly, addition of the dual ALK-MET inhibitor crizotinib 
was able to restore sensitivity to combined vemurafenib and panitumumab in MET transduced cells 
(Figure 3B). 
In vitro modeling of acquired resistance in cancer cell lines has proven effective in identifying 
resistance mechanisms that occur clinically (14,15). From a comprehensive effort aimed at defining 
the molecular landscape of resistance to targeted therapy combinations in BRAF mutant CRC cell 
lines (16), we detected the emergence of MET increased gene copy number and overexpression 
(Figure 3C) in a drug resistant WiDr subline (WiDr Res.) obtained by prolonged exposure of 
parental cells with cetuximab in association with the BRAF inhibitor encorafenib and the selective 
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PI3K-α inhibitor alpelisib (Figure 3D), a triplet regimen that is being tested in clinical trials (1). 
Functional experiments indicated that ectopic expression of MET in WiDr parental cells is able to 
confer resistance not only to combined BRAF and EGFR blockade, but also to the triplet regimen 
that includes PI3K inhibition (Figure 3D). WiDr resistant derivatives exhibited basal levels of 
activated RAS-GTP protein (Supplementary Figure S3) and constitutive phosphorylation of ERK 
despite combinatorial treatment with encorafenib+cetuximab+alpelisib (Figure 3E). WiDr resistant 
cells displaying MET amplification were clearly refractory to EGFR, BRAF and MEK targeted 
therapies, either as single agents or in combination (Figure 3F). Importantly, crizotinib alone showed 
no effects on the proliferation of WiDr resistant cells, whereas its combination with BRAF kinase 
inhibition by vemurafenib led to a marked decrease of cell viability over prolonged times (Figure 
3F).  
Altogether, these results directly underpin a causal relationship between MET amplification and 
resistance to targeted therapy combinations in BRAF mutant CRC and suggest a potential therapeutic 
strategy to overcome MET-mediated resistance. 
Subsequent MET and BRAF targeted therapy overcomes clinical resistance to EGFR-BRAF 
dual block 
The subsequent clinical history of the patient is again summarized in Figure 1. After 2 cycles of 
TAS-102, pelvic pain became severe and opioids were insufficient to achieve optimal symptom 
relief. Disease re-assessment with CT and FDG-PET/CT scans confirmed the rapid progression of the 
disease both loco-regionally (pelvic relapse with penis bulbs involvement and bilateral inguinal 
lymph nodes) and in the liver (Figure 4A). Prescription of regorafenib was contraindicated due to 
urinary fistula. In absence of further treatment options, based on tumor genotyping and preclinical 
data, and after ethical approval, combined MET and BRAF inhibition was considered as a rationale 
choice. Given the recent phase 1 data of crizotinib and vemurafenib combination (17), the patient 
started this combinatorial regimen in January 2016. After one week from treatment start, pelvic pain 
completely disappeared and the use of opioids was dramatically reduced. After 10-day treatment, a 
FDG-PET/CT scan showed an early and dramatic metabolic response (Figure 4B). Serum CA19-9 
marker declined by >50% after only 2 weeks, and almost by 90% after 4 weeks (Figure 1). 
Treatment is still ongoing without significant toxicity.  
Discussion 
In this case study, we found for the first time that MET amplification and protein over-expression was 
the main molecular driver of clinical resistance to an anti-EGFR plus BRAFi combination. MET 
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amplification has been previously identified as a mechanism of resistance to targeted agents in other 
settings, including BRAF mutated melanoma treated with vemurafenib (10,18,19). MET amplification 
was also found in approximately 5%-20% of EGFR-mutated non-small cell lung cancers with 
acquired resistance to EGFR tyrosine kinase inhibitors (20) and in 10-20% RAS/BRAF wild-type 
CRC at progression upon anti-EGFR monoclonal antibodies (9). It was previously reported that MET 
amplification emerges in malignancies with pre-existing clones of MET amplified cells (21), which 
undergo positive selection during anti-EGFR based therapy in both NSCLC and CRC patients (10). 
The same seems to be true for the patient in our study, as molecular and histological analyses 
identified the presence of a subpopulation of MET amplified cells in the tumor sample before 
treatment with BRAF targeted therapy. The percentage of cells carrying MET gene copy 
amplification increased by at least five-fold in the post-treatment liver biopsy, indicating that dual 
EGFR-BRAF blockade had positively selected for MET amplified clones.  We argue that the 
presence of a detectable fraction of pre-existing MET amplified cells has impacted negatively on the 
duration of response to dual EGFR and BRAF blockade, which was relatively short-lived. It is 
possible that in this case, combining upfront EGFR, MET and BRAF inhibition might have led to a 
more durable response and we suggest that future clinical studies should further investigate this 
aspect.  
 The proportion of BRAF mutant colorectal tumor samples co-harboring MET molecular alterations is 
unknown, but a large series of 1115 samples from any tumor types has previously reported that MET 
amplification was associated with a higher prevalence of BRAF mutation compared with non-
amplified tumors (22). In our collection of 17 additional BRAF mutant CRC samples from 
chemonaive patients, we were able to find MET amplified subclones in three cases,  
Although none of the three patients actually received BRAF target agents, it is tempting to speculate 
that subclonal genetic diversity in these tumors could negatively influence the duration of response to 
BRAF combinatorial therapies due to likely clonal selection of MET amplification, On the other 
hand, it is possible that MET amplification could also be implicated in de novo resistance to target 
therapy combinations in BRAF mutant colorectal cancer. Pre-treatment tumor samples from non-
responding patients enrolled in phase I-II studies with BRAFi combination therapies (2-6) will be 
essential to address this clinically relevant question. 
Our preclinical experiments indicated that MET amplification emerged also as a driving mechanism 
of resistance in BRAF mutant CRC cells selected with cetuximab in combination with the BRAFi 
encorafenib and the PI3K inhibitor alpelisib. Ectopic overexpression of MET was able to confer 
resistance not only to panitumumab plus vemurafenib but also to the above clinically relevant triplet 
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which includes PI3K inhibition (1). This strongly suggests that MET activation is able to confer 
resistance to several BRAFi+EGFRi-based combinations, irrespective of the specific drugs used. 
Pharmacological data in CRC cells indicated that MET inhibition alone was ineffective to overcome 
resistance and that crizotinib should be combined with BRAF blockade to affect the proliferation of 
MET-overexpressing cells both in short-term and in long-term growth assays. This is consistent with 
what has been reported very recently in BRAF inhibitor resistant melanoma patient derived xenograft 
models, in which only combined vertical blockade of the pathway with MET and BRAF inhibitors 
was shown to induce durable regression in mice (23).  
Based on preclinical modeling and functional characterization of MET aberrant signaling as a 
resistance mechanism to BRAF and EGFR dual blockade, the patient was treated with the 
combination of crizotinib and vemurafenib. The ALK inhibitor crizotinib is well known to bind also 
to MET tyrosine kinase domain and has shown clinical activity in MET amplified cancers (24,25). 
Moreover, recent phase 1 data showed that crizotinib may be safely combined with vemurafenib 
without occurrence of significant dose-limiting toxicities (17). Imaging revealed that switching from 
EGFR to MET blockade, while maintaining BRAF inhibition induced an extremely rapid and 
dramatic response following the initiation of treatment with crizotinib plus vemurafenib.  
In this case, molecular analysis of a single-lesion biopsy did not identify any additional MAPK 
pathway molecular alterations beyond MET amplification that could eventually lead to treatment 
failure. Yet we admit that our strategy could have missed other resistance alterations occurring at 
subclonal level in the same lesion or as main drivers in other disease sites, since tumor heterogeneity 
may lead to the simultaneous selection of several inter- or intra-metastatic clones carrying different 
mechanisms of secondary resistance (26). However, metabolic response was observed across all 
disease sites, with ex juvantibus confirmation that MET might have been driving resistance in a 
relatively dominant and homogeneous fashion in this individual case of BRAF-mutated CRC. We 
acknowledge that early assessment with FDG-PET/CT may not be routinely accepted as an endpoint 
of treatment activity. However, the role of early metabolic response has gained robust evidence since 
the introduction of targeted therapies. In the era of precision medicine, the dramatic FDG-PET/CT 
response, necessarily coupled with the clinical and laboratory data, is indicative of immediate 
treatment benefit – even if longer follow up is needed to assess the duration of such benefit and 
potential emergence of further resistance mechanisms. 
Extreme caution should be applied not to over-interpret the implications of this work.  Indeed, we are 
well aware of the potential pitfalls of selecting a targeted therapy strategy based on the molecular 
profile of a single resistant lesion, as exemplified by recent case reports in CRC and breast cancer 
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patients (26, 27). Nevertheless, we believe that this case study may highly impact future research. In 
fact, specific targeting of MET-driven resistance to dual EGFR and BRAF block may lead to the 
design of biomarker-driven trials of second-line targeted therapy. Triple EGFR, MET and BRAF co-
inhibition may also be investigated as additional strategy to prevent or overcome resistance in 
molecularly selected patients.  
Methods 
Patient Care and Specimen Collection 
Tumor samples were collected in accordance with an Institutional Review Board–approved protocol, 
to which the patient provided written informed consent, and all studies were conducted in accordance 
with the Declaration of Helsinki. Targeted NGS on clinical specimens using was performed in the 
Department of Diagnostic Pathology and Laboratory Medicine at Fondazione IRCCS Istituto 
Nazionale dei Tumori, Milan, Italy. The patient's insurance company covered the cost of off-label 
combinatorial therapies (panitumumab+ vemurafenib; crizotinib+vemurafenib), to which the patient 
gave informed consent. CT scans were obtained as part of routine clinical care, while FDG-PET/CT 
scans were performed as part of an ancillary study protocol for patients receiving targeted treatments. 
The clinical course of the patient is summarized in Figure 1.  
Next-generation sequencing 
Next Generation Sequencing (NGS) analysis was performed as detailed in the Supplementary 
Methods and in Supplementary Table S2.  
Immunohistochemistry 
Immunohistochemistry (IHC) was performed on 3 μm formalin fixed paraffin-embedded (FFPE) 
tissue sections or on WiDr cytoclots. MET protein expression was detected by using a rabbit 
monoclonal anti-MET antibody (dilution 1:200; clone SP44, Spring Bioscience, Pleasanton, CA), 
directed against the synthetic peptide derived from C-terminus of human MET displaying 
membranous and/or cytoplasmic epitope. Other information is provided in the Supplementary 
Methods. 
In situ hybridization (SISH and FISH)  
MET gene status was assessed respectively by both SISH and FISH analyses scored blindly by two 
observers (A.G. and E.V.). Bright field dual-color SISH analysis was performed on 3 μm FFPE tissue 
sections by using the MET DNP Probe along with the Chromosome 7 DIG Probe (Ventana Medical 
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Systems) on a BenchMark Ultra Platform (Ventana Medical Systems) according to the manufacture’s 
protocol. Dual color FISH analysis, both on metaphase chromosomes and interphase nuclei, obtained 
from WiDr cultured cells and on 3 μm FFPE tissue sections, was performed by using D7Z1 (7p11.1-
q11.1) / c-MET (7q31.2) probes (Cytocell), respectively labelled with FITC and Texas Red. 
Procedure information is described in the Supplementary Methods.  
For both SISH and FISH analyses the probes signals were counted in at least 100 non overlapping 
tumor cells nuclei from each case. Two independent molecular pathologists (A.G. and E.V.) scored 
the slides in a blinded fashion. MET gene amplification was defined as positive when: a) MET/CEP7 
ratio was > 2 or b) average number of MET signals per tumor cell nucleus was > 6.  
SISH analyses for MET status were also performed on archival tumor tissue of 17 advanced 
colorectal tumors carrying mutant BRAF V600E diagnosed at Fondazione IRCCS Istituto Nazionale 
dei Tumori from 2012 to 2016. 
Similarly, HER2 gene amplification was defined as positive when: a) HER2/CEP17 ratio was > 2 or 
b) average number of HER2 signals per tumor cell nucleus was > 6. 
Bright field dual-color SISH analysis was performed for MDM2 by using the MDM2 DNP Probe 
along with Chromosome 12 DIG Probe (Ventana Medical Systems) on a BenchMark Ultra Platform 
(Ventana Medical Systems) according to the manufacture’s protocol. 
Cell lines and Treatments 
WiDr parental cells were obtained from Dr René Bernards (Amsterdam, The Netherlands) in July 
2011. The KRAS mutant SW480 cell line was purchased from ATCC (LGC Promochem) in January 
2011.  All cells were cultured at 37°C and 5% CO2 in RPMI 1640 (Invitrogen), supplemented with 
10% fetal bovine serum, 2 mM L-glutamine and antibiotics (100 U/ml penicillin and 100 mg/ml 
streptomycin). The genetic identity of parental cell lines and their resistant derivatives was 
authenticated by short tandem repeat profiling (Cell ID System; Promega) at 10 different loci 
(D5S818, D13S317, D7S820, D16S539, D21S11, vWA, TH01, TPOX, CSF1PO and amelogenin) 
not fewer than 2 months before drug profiling or biochemical experiments. Cell lines were tested and 
resulted negative for Mycoplasma contamination with the VenorGeM Classic Kit (Minerva Biolabs). 
WiDr were made resistant by continuous drug exposure to the combination of cetuximab (5 μg/ml), 
encorafenib (1 μM) and alpelisib (0.5 μM). A detailed protocol of the drug proliferation assays is 
reported in the Supplementary Methods. 
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Western Blot analysis 
Total cellular proteins was extracted by lysing cells in boiling Laemmli buffer (1% SDS, 50 mM 
Tris-HCl [pH 7.5], 150 mM NaCl). The following primary antibodies were used (all from Cell 
Signaling Technology, except where otherwise indicated): anti-MET (clone D1C2, 1:1000); anti-
phospho MET (Tyr1234/1235, Cat.#3126; 1:1,000); anti-phospho p44/42 ERK (Thr202/Tyr204; 
1:1,000); anti-p44/42 ERK (1:1,000); anti-phospho AKT (Ser473; 1:1,000); anti-AKT (1:1,000); 
HSP90 (Santa Cruz Biotechnology; 1:500). 
Viral Infection 
Lentiviral vector stock were produced by transient transfection of the pCCL-MET wild-type or lenti-
control plasmid (a gift of Elisa Vigna, IRCCS, Candiolo, Turin) the packaging plasmid MDLg/pRRE 
and pRSV.REV, and the vesicular stomatitis virus (VSV) envelope plasmid pMD2.VSV-G (25, 2.5, 
6.25 and 9 µg, respectively, for 15-cm dishes) in HEK-293T cells in presence of 1mM/L sodium 
butyrate (Sigma) and 10 ng/ml of Doxicicline. Cells were tranduced in six well plates (3 x 105 per 
well in 2 ml of medium) in the presence of polybrene (8 µg/ml) (Sigma). 
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Figure 1. Summary of patient clinical history.  
The clinical course of the patient with colorectal cancer is summarized, with serum cancer antigen 
19-9 tumor marker levels shown throughout treatment (green line). Shaded boxes indicate periods of 
administration of the indicated chemotherapeutic agents. Blue vertical lines indicate timing of tumor 
specimen acquisition from surgical procedures or biopsy, as well as dates of tumor assessment by 
either CT scan or FDG-PET/CT scan.  
Figure 2. MET amplification is selected for in a BRAF mutant CRC biopsy from a patient who 
developed resistance to combined BRAF and EGFR targeted treatments 
In panel A, baseline CT scan prior to start of panitumumab and vemurafenib, showing liver 
involvement; in panel B, partial response to treatment according to RECIST 1.1 at week 8; in panel 
C, progressive disease during treatment at week 16. 
In panel A1-4 and C1-4: analyses performed on archival surgical specimen and on post-progression 
liver rebiopsy, respectively. A1-C1. Conventionally stained section using Hematoxylin & Eosin, 
showing poorly differentiated carcinoma of the rectum (A1) and liver metastasis (C1) (A1-C1, 
original magnification x20); A2-C2. Immunohistochemical detection of MET protein. The primary 
tumor displays heterogeneous immunostaining ranging from weak to moderate (at the center) 
intensity (A2). Metastatic tumor cells display homogeneous, strong immunostaining (C2) (A2-C2, 
original magnification X20); A3-C3. Dual color bright field in situ hybridization (ISH) for MET gene 
(black dots) and CEP7 (red dots). The primary tumor, though not amplified, display heterogeneous, 
MET gene copy number, ranging from 1 to 7 (A3). Metastatic tumors cells contain high MET gene 
copy number (ranging from 2 to 20) featuring MET gene amplification (C3) (A3-C3, original 
magnification X20). A4-C4. Dual color FISH analysis using D7Z1 (7p11.1-q11.1) / c-MET (7q31.2) 
probes (Cytocell), respectively labeled with FITC and Texas Red. The primary tumor (A4, original 
magnification x100) shows heterogeneous, MET gene copy number, ranging from 1 to 8, while 
metastatic tumors cells (C4, original magnification x100) contain high MET gene copy number 
(ranging from 2 to 30) featuring MET gene amplification.  
Figure 3. MET overexpression or gene amplification confers resistance to targeted therapy 
combinations in BRAF mutant CRC cells. A, BRAF mutant WiDr cells were transduced with 
either control (empty) or MET–expressing lentiviral vectors. Cells were then treated with 
vemurafenib (2 μM), panitumumab (5 μg/ml) and their combination for 5 hours prior to protein 
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extraction and Western blotting with total MET, phosphorylated–MET (Tyr 1234-1235), total AKT, 
phosphorylated-AKT (Ser473), total ERK1/2 and phosphorylated-ERK1/2 (Thr 202 /Tyr 204) 
antibodies. HSP90 was included as a loading control. B, After 96-hour treatment with panitumumab 
(5 μg/ml), vemurafenib (1 μM), crizotinib (0.3 μM) or their combinations, the viability of empty or 
lenti-MET transduced cells was assessed by relative ATP content measurement. Results represent 
mean ± SD of at least 2 independent observations, each performed in triplicate. ** P<0.01; *** 
P<0.001 Bonferroni’s adjusted ANOVA p values; C, FISH analysis and immunohistochemistry 
(IHC) showing MET gene amplification (top) and MET protein overexpression (bottom), 
respectively, in WiDr resistant derivatives (WiDr res) generated from WiDr parental (WiDr par) cells 
after several weeks’ continuous treatment with the triple combination 
encorafenib+cetuximab+alpelisib; MET (7q31)–specific probe is labeled with Texas red, whereas 
chromosome 7 centromeric probe D7Z1 (7p11.1–q11.1) is marked in green. FISH, original 
magnification 100×; IHC, original magnification ×40; D, Cell viability by ATP assay of WiDr 
parental cells and resistant derivatives, as well as WiDr transduced with MET after treatment for 96 
hours with the indicated molar concentrations of encorafenib in association with constant 5 μg/ml 
cetuximab and 0.5 μM alpelisib. Results represent mean ± SD of at least 2 independent observations, 
each performed in triplicate. E, WiDr parental cells and their MET amplified subline with acquired 
resistance to the triple combination encorafenib+cetuximab+alpelisib were treated with the 
combination of encorafenib (0.4 μM), cetuximab (5 μg/ml) and alpelisib (1 μM) for 5 hours prior to 
protein extraction and Western blotting with the indicated antibodies. F, Long-term colony forming 
assay of MET amplified encorafenib+cetuximab+alpelisib resistant WiDr cells treated for 12-14 days 
in the absence or presence of panitumumab (EGFRi,  5 μg/ml), trametinib (MEKi, 10 nM),  crizotinib 
(0.3 μM), vemurafenib (BRAFi, 1.5 μM) or their combinations. Results are representative of at least 
2 independent observations.  
Figure 4. 18F-FDG PET/C T scans at baseline and 10 days after the start of combination treatment 
with crizotinib and vemurafenib. Panel A (coronal and axial fused images) shows liver metastases 
(red arrows) and pelvic/inguinal lymph node involvement (white arrows) at baseline. Panel B 
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Supplementary Figure S1. Copy number increase of MDM2 gene at progression after 
vemurafenib+panitumumab. 
In panel A and B: analyses performed on archival surgical specimen and on post-progression 
liver rebiopsy, respectively. Dual color bright field in situ hybridization (ISH) for MDM2 gene 
(black dots) and CEP12 (chromosome twelve α-centromeric, red dots). In baseline tumor tissue, 
the signals corresponding to the MDM2 and CEP12 probes ranged from 2 to 5 (mean values of 
3.5 and 3.3 for MDM2 and CEP12, respectively), with a gene-to-chromosome ratio of just over 
1, indicating absence of gene amplification. However, in a small fraction of cells (5%) within the 
pre-treatment sample the MDM2 gene copy number was ≥5. In the post-progression tumor 
biopsy, MDM2 copy number varied from 3 to 16 (mean 7.2) while CEP12 ranged from 1 to 8 
(mean 3.4). At least 75% cells in the post-treatment liver biopsy were found to carry ≥5 MDM2 
gene copy number and the gene-to-chromosome ratio was >2. Original magnification X20.  
 
Supplementary Figure S2. A-D. Representative examples of colorectal carcinomas bearing 
BRAF mutations and MET gene copy number gain. 
A Hematoxylin & Eosin staining of a poorly differentiated colon carcinoma. B Dual color bright 
field ISH for MET gene (black dots) and CEP7 (red dots) of case in panel A. Tumor cells contain 
MET gene copy number (ranging from 2 to 7; mean: 4.2) and Chromosome 7 signals (ranging 
from 2 to 5; mean: 3.4). Interestingly, 38% of neoplastic cells featured ≥ 5 MET gene copy 
number. C Hematoxylin & Eosin staining of a pancreatic lesion from an intestinal 
adenocarcinoma. D Single color bright field ISH for MET gene (black dots) of case in panel C. 
Tumor cells contain MET gene copy number (ranging from 4 to 11; mean: 5.4). Up to 77% of 
tumor cells contained ≥ 5 MET gene copy number. Arrows indicate neoplastic cells with high 
MET gene copy number. 
 
Supplementary Figure S3.  Untreated WiDr parental cells exhibit similar levels of activated 
RAS-GTP protein compared to their MET-amplified resistant derivatives treated with 
encorafenib+cetuximab+alpelisib (E+C+A). Whole-cell extracts were subjected to pull-down 
of active KRAS-GTP using the GST-RAF1 Ras-binding domain. Lysate of SW480 colorectal 
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Preparation of cytoclots 
WiDr cytoclots were prepared by pelleting up to 50x106 cells and re-suspending them in 1% agar, 
followed by polymerization in dry ice for a few seconds, fixation in paraformaldehyde 4% and 
ethanol 70% at +4°C for 4 hours, and final embedding in paraffin wax.  
Immunohistochemistry 
IHC was carried out on a BenchMark Ultra Platform (Ventana Medical Systems, Tucson, AZ) by 
using the OptiviewDAB Detection Kit (Ventana Medical Systems). MET IHC was evaluated 
according to a semi-quantitative assessment (H-score) which combines staining intensity (scored 
from 0 to 4) with the percentage of positive cells (scored 0–100%). Each individual intensity level 
is multiplied by the percentage of cells and all values are added to obtain the final IHC score, 
ranging from 0 to 400. Scores from 0 to 200 are considered negative/low expression and scores 
from 201 to 400 are considered positive/high expression. 
HER2 protein expression was evaluated by using the anti-human c-erbB-2 A0485 polyclonal 
antibody (dilution 1:1500; Dako Denmark A/S, Glostrup, Denmark) on a DakoAutostainer Plus by 
using the EnVision® FLEX+ (Dako) detection system. HER2 immunoreactivity was evaluated 
according to previously described scoring systems (1). 
Fluorescence In Situ Hybridization 
For both cell lines and clinical samples dehydration was carried out in ethanol series (70%, 90%, 
100%), followed by 3 washes (5’ each) and air drying. Probes and target DNA were co-denatured 
for 5 min at 75 °C and then hybridized overnight at 37 °C. Slides were washed with washing 
solution I (0.4x SSC, 0.3% NP-40) for 5 min at 73 °C, for 1 min with washing solution II (2x 
SSC/0.1% NP-40) at room temperature (Abnova) and finally counterstained with 4′,6-diamidino-2-
phenylindole (DAPI). FISH signals were evaluated with a Zeiss Axioscope Imager.Z1 (Zeiss) 
equipped with single and triple band pass filters.  
Next-generation sequencing 
DNA extraction was performed as previously described (2). Next Generation Sequencing (NGS) 
analysis was performed by using small genomic DNA samples (20 ng/l) and the Ion-TorrentTM 
Personal Genome Machine platform (Life Technologies-Thermo Fisher Scientific, USA). A 
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detailed description of the applied T-NGS procedures has been previously published (2). For this 
study, we used two custom panels, the first of which designed to amplify 3358 amplicons (246,15 
kb) from 110 oncogenes and tumor suppressor genes recurrently mutated in human cancers and a 
second custom panel to analyze 26 amplicons (2,77 kb) corresponding to the EGFR extra-cellular 
region (exons from 1 to 14), as detailed in Supplementary Table S1.  
Drug proliferation assays 
Vemurafenib, trametinib and encorafenib were purchased from Sequoia Chemicals; crizotinib and 
alpelisib were from Selleckchem and ChemieTek respectively. The EGFR targeted monoclonal 
antibodies cetuximab and panitumumab were obtained from the Pharmacy at Ospedale Niguarda, 
Milan. Cell proliferation experiments were carried out in 96-well plates in triplicate. A total of 
2,000 cells/well were seeded in 100 µl complete growth medium. At 24 hours post-seeding, 100 µl 
of serum-free medium with or without cetuximab or panitumumab (both 5 μg/ml) was manually 
added to the cells. All other drugs were added directly on the plate by TECAN D300e digital 
dispenser (HP). After 72-96 hours’ treatment cell viability was assessed by ATP content using 
CellTiter-Glo Luminescent Assay (Promega). Viability was normalized as a percentage of control 
untreated cells. Data from growth-inhibition assays were plotted using the nonlinear regression 
curve fit modelling from GraphPad Prism-6 (GraphPad Software). For long-term proliferation 
assays, cells were seeded in 6-well plates (20,000 cells/well) and cultured in the absence and 
presence of drugs as indicated. Wells were fixed with 4% paraformaldehyde and stained with 1% 
crystal violet-methanol solution (Sigma-Aldrich) after 12-14 days. All assays were performed 
independently at least two times. 
RAS Activation Assay 
GST-RAF1-RAS-binding domain fusion protein expression was induced in Escherichia coli for 3 hr 
at 30°C with 0.2 mM isopropyl-1-thioβ-D-galactopyranoside. Bacterial pellet was resuspended in 
lysis buffer (PBS, 1 mM PMSF, 5 mM β-mercaptoethanol, mixture of protease inhibitors) and 
sonicated. The soluble GST tagged proteins were isolated with glutathione agarose beads. Forty 
micrograms of purified proteins were then incubated with 2 mg of whole-cell cleared lysate. The 
complexes were collected by centrifugation and analyzed by western blot using an anti-KRAS 
monoclonal antibody (clone 3B10-2F2; Sigma-Aldrich; 1:500). Twenty microgram of total lysates 
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Supplementary Table S1. List of genes and exons analyzed by targeted next-generation 
sequencing. 
GENE-EXON Reference Chromosome CHR_Start CHR_End STRAND 
ARID1A GRCh37/hg19 chr1 27022890 27024036 + 
ARID1A GRCh37/hg19 chr1 27056137 27056359 + 
ARID1A GRCh37/hg19 chr1 27057638 27058100 + 
ARID1A GRCh37/hg19 chr1 27059162 27059288 + 
ARID1A GRCh37/hg19 chr1 27087342 27087592 + 
ARID1A GRCh37/hg19 chr1 27087870 27087969 + 
ARID1A GRCh37/hg19 chr1 27088638 27088815 + 
ARID1A GRCh37/hg19 chr1 27089459 27089781 + 
ARID1A GRCh37/hg19 chr1 27092707 27092862 + 
ARID1A GRCh37/hg19 chr1 27092943 27093062 + 
ARID1A GRCh37/hg19 chr1 27094276 27094495 + 
ARID1A GRCh37/hg19 chr1 27097605 27097822 + 
ARID1A GRCh37/hg19 chr1 27098986 27099128 + 
ARID1A GRCh37/hg19 chr1 27099298 27099483 + 
ARID1A GRCh37/hg19 chr1 27099832 27099992 + 
ARID1A GRCh37/hg19 chr1 27100066 27100213 + 
ARID1A GRCh37/hg19 chr1 27100288 27100394 + 
ARID1A GRCh37/hg19 chr1 27100815 27101716 + 
ARID1A GRCh37/hg19 chr1 27102063 27102203 + 
ARID1A GRCh37/hg19 chr1 27105509 27107252 + 
ATRX GRCh37/hg19 chrX 76763824 76764112 - 
ATRX GRCh37/hg19 chrX 76776261 76776399 - 
ATRX GRCh37/hg19 chrX 76776876 76776981 - 
ATRX GRCh37/hg19 chrX 76777736 76777871 - 
ATRX GRCh37/hg19 chrX 76778725 76778884 - 
ATRX GRCh37/hg19 chrX 76812917 76813121 - 
ATRX GRCh37/hg19 chrX 76814135 76814322 - 
ATRX GRCh37/hg19 chrX 76829710 76829828 - 
ATRX GRCh37/hg19 chrX 76845299 76845415 - 
ATRX GRCh37/hg19 chrX 76849161 76849324 - 
ATRX GRCh37/hg19 chrX 76854875 76855054 - 
ATRX GRCh37/hg19 chrX 76855196 76855294 - 
ATRX GRCh37/hg19 chrX 76855898 76856038 - 
ATRX GRCh37/hg19 chrX 76872076 76872203 - 
ATRX GRCh37/hg19 chrX 76874269 76874454 - 
ATRX GRCh37/hg19 chrX 76875858 76876005 - 
ATRX GRCh37/hg19 chrX 76888690 76888877 - 
ATRX GRCh37/hg19 chrX 76889049 76889205 - 
ATRX GRCh37/hg19 chrX 76890080 76890199 - 
ATRX GRCh37/hg19 chrX 76891401 76891552 - 
ATRX GRCh37/hg19 chrX 76907599 76907848 - 
ATRX GRCh37/hg19 chrX 76909583 76909695 - 
ATRX GRCh37/hg19 chrX 76912045 76912148 - 
ATRX GRCh37/hg19 chrX 76918866 76919052 - 
ATRX GRCh37/hg19 chrX 76920129 76920272 - 
ATRX GRCh37/hg19 chrX 76931716 76931798 - 
ATRX GRCh37/hg19 chrX 76937007 76940090 - 
ATRX GRCh37/hg19 chrX 76940426 76940503 - 
ATRX GRCh37/hg19 chrX 76944306 76944425 - 
ATRX GRCh37/hg19 chrX 76949308 76949431 - 
ATRX GRCh37/hg19 chrX 76952060 76952197 - 
ATRX GRCh37/hg19 chrX 76953066 76953128 - 
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ATRX GRCh37/hg19 chrX 76954057 76954122 - 
ATRX GRCh37/hg19 chrX 76972603 76972725 - 
ATRX GRCh37/hg19 chrX 77041463 77041492 - 
BAP1 GRCh37/hg19 chr3 52436299 52436442 - 
BAP1 GRCh37/hg19 chr3 52436613 52436695 - 
BAP1 GRCh37/hg19 chr3 52436790 52436892 - 
BAP1 GRCh37/hg19 chr3 52437149 52437319 - 
BAP1 GRCh37/hg19 chr3 52437427 52437915 - 
BAP1 GRCh37/hg19 chr3 52438464 52438607 - 
BAP1 GRCh37/hg19 chr3 52439121 52439315 - 
BAP1 GRCh37/hg19 chr3 52439776 52439933 - 
BAP1 GRCh37/hg19 chr3 52440264 52440397 - 
BAP1 GRCh37/hg19 chr3 52440840 52440928 - 
BAP1 GRCh37/hg19 chr3 52441185 52441337 - 
BAP1 GRCh37/hg19 chr3 52441410 52441481 - 
BAP1 GRCh37/hg19 chr3 52441969 52442098 - 
BAP1 GRCh37/hg19 chr3 52442485 52442627 - 
BAP1 GRCh37/hg19 chr3 52443565 52443629 - 
BAP1 GRCh37/hg19 chr3 52443725 52443764 - 
BAP1 GRCh37/hg19 chr3 52443853 52443899 - 
BAX GRCh37/hg19 chr19 49458181 49458224 + 
BAX GRCh37/hg19 chr19 49458800 49458861 + 
BAX GRCh37/hg19 chr19 49458939 49459095 + 
BAX GRCh37/hg19 chr19 49459450 49459595 + 
BAX GRCh37/hg19 chr19 49464062 49464359 + 
BAX GRCh37/hg19 chr19 49464784 49464898 + 
BLM GRCh37/hg19 chr15 91290618 91290725 + 
BLM GRCh37/hg19 chr15 91292592 91293302 + 
BLM GRCh37/hg19 chr15 91295012 91295181 + 
BLM GRCh37/hg19 chr15 91298036 91298173 + 
BLM GRCh37/hg19 chr15 91303372 91303514 + 
BLM GRCh37/hg19 chr15 91303819 91304490 + 
BLM GRCh37/hg19 chr15 91306191 91306392 + 
BLM GRCh37/hg19 chr15 91308521 91308649 + 
BLM GRCh37/hg19 chr15 91310135 91310258 + 
BLM GRCh37/hg19 chr15 91312358 91312466 + 
BLM GRCh37/hg19 chr15 91312663 91312821 + 
BLM GRCh37/hg19 chr15 91326047 91326163 + 
BLM GRCh37/hg19 chr15 91328146 91328316 + 
BLM GRCh37/hg19 chr15 91333874 91334079 + 
BLM GRCh37/hg19 chr15 91337392 91337592 + 
BLM GRCh37/hg19 chr15 91341415 91341572 + 
BLM GRCh37/hg19 chr15 91346746 91346955 + 
BLM GRCh37/hg19 chr15 91347392 91347594 + 
BLM GRCh37/hg19 chr15 91352362 91352494 + 
BLM GRCh37/hg19 chr15 91354430 91354641 + 
BLM GRCh37/hg19 chr15 91358327 91358514 + 
CDK4 GRCh37/hg19 chr12 58142303 58142405 - 
CDK4 GRCh37/hg19 chr12 58142960 58143105 - 
CDK4 GRCh37/hg19 chr12 58143232 58143292 - 
CDK4 GRCh37/hg19 chr12 58144434 58144553 - 
CDK4 GRCh37/hg19 chr12 58144701 58144878 - 
CDK4 GRCh37/hg19 chr12 58144985 58145130 - 
CDK4 GRCh37/hg19 chr12 58145278 58145505 - 
DAXX GRCh37/hg19 chr6 33286515 33286584 - 
DAXX GRCh37/hg19 chr6 33286769 33287001 - 
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DAXX GRCh37/hg19 chr6 33287152 33287636 - 
DAXX GRCh37/hg19 chr6 33287783 33288006 - 
DAXX GRCh37/hg19 chr6 33288152 33288373 - 
DAXX GRCh37/hg19 chr6 33288508 33289349 - 
DAXX GRCh37/hg19 chr6 33289491 33289707 - 
DAXX GRCh37/hg19 chr6 33290634 33290696 - 
FANCM GRCh37/hg19 chr14 45605230 45605747 + 
FANCM GRCh37/hg19 chr14 45606267 45606449 + 
FANCM GRCh37/hg19 chr14 45609830 45609917 + 
FANCM GRCh37/hg19 chr14 45618035 45618203 + 
FANCM GRCh37/hg19 chr14 45620595 45620736 + 
FANCM GRCh37/hg19 chr14 45623118 45623260 + 
FANCM GRCh37/hg19 chr14 45623895 45624030 + 
FANCM GRCh37/hg19 chr14 45624571 45624667 + 
FANCM GRCh37/hg19 chr14 45628294 45628488 + 
FANCM GRCh37/hg19 chr14 45633557 45633773 + 
FANCM GRCh37/hg19 chr14 45636148 45636371 + 
FANCM GRCh37/hg19 chr14 45639787 45639954 + 
FANCM GRCh37/hg19 chr14 45642253 45642418 + 
FANCM GRCh37/hg19 chr14 45644269 45646184 + 
FANCM GRCh37/hg19 chr14 45650628 45650732 + 
FANCM GRCh37/hg19 chr14 45650835 45650913 + 
FANCM GRCh37/hg19 chr14 45652972 45653110 + 
FANCM GRCh37/hg19 chr14 45654415 45654581 + 
FANCM GRCh37/hg19 chr14 45656979 45657095 + 
FANCM GRCh37/hg19 chr14 45658000 45658570 + 
FANCM GRCh37/hg19 chr14 45665370 45665755 + 
FANCM GRCh37/hg19 chr14 45667842 45668143 + 
FANCM GRCh37/hg19 chr14 45669068 45669216 + 
FGFR4 GRCh37/hg19 chr5 176516599 176516699 + 
FGFR4 GRCh37/hg19 chr5 176517386 176517659 + 
FGFR4 GRCh37/hg19 chr5 176517741 176517831 + 
FGFR4 GRCh37/hg19 chr5 176517934 176518110 + 
FGFR4 GRCh37/hg19 chr5 176518681 176518814 + 
FGFR4 GRCh37/hg19 chr5 176519317 176519517 + 
FGFR4 GRCh37/hg19 chr5 176519642 176519790 + 
FGFR4 GRCh37/hg19 chr5 176520134 176520337 + 
FGFR4 GRCh37/hg19 chr5 176520328 176520557 + 
FGFR4 GRCh37/hg19 chr5 176520650 176520781 + 
FGFR4 GRCh37/hg19 chr5 176522326 176522446 + 
FGFR4 GRCh37/hg19 chr5 176522529 176522729 + 
FGFR4 GRCh37/hg19 chr5 176523053 176523185 + 
FGFR4 GRCh37/hg19 chr5 176523283 176523363 + 
FGFR4 GRCh37/hg19 chr5 176523600 176523747 + 
FGFR4 GRCh37/hg19 chr5 176524288 176524403 + 
FGFR4 GRCh37/hg19 chr5 176524523 176524682 + 
FHIT GRCh37/hg19 chr3 59737947 59738052 - 
FHIT GRCh37/hg19 chr3 59908067 59908145 - 
FHIT GRCh37/hg19 chr3 59997092 59997131 - 
FHIT GRCh37/hg19 chr3 59999728 59999883 - 
FHIT GRCh37/hg19 chr3 60522588 60522700 - 
FLT1 GRCh37/hg19 chr13 28877299 28877510 - 
FLT1 GRCh37/hg19 chr13 28880810 28880914 - 
FLT1 GRCh37/hg19 chr13 28882975 28883069 - 
FLT1 GRCh37/hg19 chr13 28885722 28885874 - 
FLT1 GRCh37/hg19 chr13 28886125 28886240 - 
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GENE-EXON Reference Chromosome CHR_Start CHR_End STRAND 
FLT1 GRCh37/hg19 chr13 28891630 28891739 - 
FLT1 GRCh37/hg19 chr13 28893555 28893676 - 
FLT1 GRCh37/hg19 chr13 28895595 28895727 - 
FLT1 GRCh37/hg19 chr13 28896394 28896501 - 
FLT1 GRCh37/hg19 chr13 28896922 28897088 - 
FLT1 GRCh37/hg19 chr13 28901594 28901692 - 
FLT1 GRCh37/hg19 chr13 28903747 28903870 - 
FLT1 GRCh37/hg19 chr13 28908157 28908271 - 
FLT1 GRCh37/hg19 chr13 28913300 28913442 - 
FLT1 GRCh37/hg19 chr13 28919577 28919693 - 
FLT1 GRCh37/hg19 chr13 28931686 28931827 - 
FLT1 GRCh37/hg19 chr13 28942710 28942805 - 
FLT1 GRCh37/hg19 chr13 28959017 28959173 - 
FLT1 GRCh37/hg19 chr13 28963833 28964246 - 
FLT1 GRCh37/hg19 chr13 28971092 28971210 - 
FLT1 GRCh37/hg19 chr13 28973176 28973260 - 
FLT1 GRCh37/hg19 chr13 28979912 28980036 - 
FLT1 GRCh37/hg19 chr13 29001291 29001460 - 
FLT1 GRCh37/hg19 chr13 29001884 29002063 - 
FLT1 GRCh37/hg19 chr13 29004182 29004309 - 
FLT1 GRCh37/hg19 chr13 29005268 29005452 - 
FLT1 GRCh37/hg19 chr13 29007951 29008097 - 
FLT1 GRCh37/hg19 chr13 29008190 29008362 - 
FLT1 GRCh37/hg19 chr13 29012353 29012487 - 
FLT1 GRCh37/hg19 chr13 29041035 29041271 - 
FLT1 GRCh37/hg19 chr13 29041653 29041759 - 
FLT1 GRCh37/hg19 chr13 29068912 29068985 - 
FLT4 GRCh37/hg19 chr5 180030187 180030395 - 
FLT4 GRCh37/hg19 chr5 180035276 180035289 - 
FLT4 GRCh37/hg19 chr5 180035963 180036058 - 
FLT4 GRCh37/hg19 chr5 180036900 180037030 - 
FLT4 GRCh37/hg19 chr5 180038326 180038484 - 
FLT4 GRCh37/hg19 chr5 180039501 180039616 - 
FLT4 GRCh37/hg19 chr5 180040006 180040115 - 
FLT4 GRCh37/hg19 chr5 180041063 180041184 - 
FLT4 GRCh37/hg19 chr5 180043362 180043494 - 
FLT4 GRCh37/hg19 chr5 180043895 180043999 - 
FLT4 GRCh37/hg19 chr5 180045765 180045925 - 
FLT4 GRCh37/hg19 chr5 180046016 180046114 - 
FLT4 GRCh37/hg19 chr5 180046248 180046371 - 
FLT4 GRCh37/hg19 chr5 180046660 180046774 - 
FLT4 GRCh37/hg19 chr5 180047168 180047313 - 
FLT4 GRCh37/hg19 chr5 180047604 180047720 - 
FLT4 GRCh37/hg19 chr5 180047871 180048012 - 
FLT4 GRCh37/hg19 chr5 180048101 180048257 - 
FLT4 GRCh37/hg19 chr5 180048537 180048909 - 
FLT4 GRCh37/hg19 chr5 180049726 180049844 - 
FLT4 GRCh37/hg19 chr5 180050930 180051066 - 
FLT4 GRCh37/hg19 chr5 180052864 180053036 - 
FLT4 GRCh37/hg19 chr5 180053106 180053270 - 
FLT4 GRCh37/hg19 chr5 180055877 180056004 - 
FLT4 GRCh37/hg19 chr5 180056254 180056432 - 
FLT4 GRCh37/hg19 chr5 180056691 180056840 - 
FLT4 GRCh37/hg19 chr5 180056938 180057110 - 
FLT4 GRCh37/hg19 chr5 180057220 180057342 - 
FLT4 GRCh37/hg19 chr5 180057550 180057804 - 
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GENE-EXON Reference Chromosome CHR_Start CHR_End STRAND 
FLT4 GRCh37/hg19 chr5 180058677 180058783 - 
FLT4 GRCh37/hg19 chr5 180076483 180076550 - 
FOXA1 GRCh37/hg19 chr14 38060565 38061921 - 
FOXA1 GRCh37/hg19 chr14 38064101 38064182 - 
GATA3 GRCh37/hg19 chr10 8097614 8097864 + 
GATA3 GRCh37/hg19 chr10 8100263 8100809 + 
GATA3 GRCh37/hg19 chr10 8105951 8106106 + 
GATA3 GRCh37/hg19 chr10 8111431 8111566 + 
GATA3 GRCh37/hg19 chr10 8115697 8115991 + 
GRM3 GRCh37/hg19 chr7 86394457 86394934 + 
GRM3 GRCh37/hg19 chr7 86415572 86416437 + 
GRM3 GRCh37/hg19 chr7 86468150 86469226 + 
GRM3 GRCh37/hg19 chr7 86479681 86479865 + 
GRM3 GRCh37/hg19 chr7 86493593 86493676 + 
IGF1R GRCh37/hg19 chr15 99192806 99192909 + 
IGF1R GRCh37/hg19 chr15 99250786 99251341 + 
IGF1R GRCh37/hg19 chr15 99434549 99434871 + 
IGF1R GRCh37/hg19 chr15 99439981 99440139 + 
IGF1R GRCh37/hg19 chr15 99442701 99442855 + 
IGF1R GRCh37/hg19 chr15 99451909 99452133 + 
IGF1R GRCh37/hg19 chr15 99454539 99454675 + 
IGF1R GRCh37/hg19 chr15 99456268 99456516 + 
IGF1R GRCh37/hg19 chr15 99459188 99459365 + 
IGF1R GRCh37/hg19 chr15 99459896 99460110 + 
IGF1R GRCh37/hg19 chr15 99465372 99465665 + 
IGF1R GRCh37/hg19 chr15 99467100 99467246 + 
IGF1R GRCh37/hg19 chr15 99467749 99467918 + 
IGF1R GRCh37/hg19 chr15 99472782 99472894 + 
IGF1R GRCh37/hg19 chr15 99473459 99473539 + 
IGF1R GRCh37/hg19 chr15 99478048 99478287 + 
IGF1R GRCh37/hg19 chr15 99478540 99478660 + 
IGF1R GRCh37/hg19 chr15 99482425 99482594 + 
IGF1R GRCh37/hg19 chr15 99486147 99486286 + 
IGF1R GRCh37/hg19 chr15 99491798 99491942 + 
IGF1R GRCh37/hg19 chr15 99500285 99500676 + 
IGF2R GRCh37/hg19 chr6 160390274 160390432 + 
IGF2R GRCh37/hg19 chr6 160412211 160412360 + 
IGF2R GRCh37/hg19 chr6 160430037 160430171 + 
IGF2R GRCh37/hg19 chr6 160431714 160431822 + 
IGF2R GRCh37/hg19 chr6 160445599 160445741 + 
IGF2R GRCh37/hg19 chr6 160448212 160448351 + 
IGF2R GRCh37/hg19 chr6 160450577 160450692 + 
IGF2R GRCh37/hg19 chr6 160453578 160453750 + 
IGF2R GRCh37/hg19 chr6 160453969 160454144 + 
IGF2R GRCh37/hg19 chr6 160455446 160455559 + 
IGF2R GRCh37/hg19 chr6 160461587 160461761 + 
IGF2R GRCh37/hg19 chr6 160464175 160464325 + 
IGF2R GRCh37/hg19 chr6 160465541 160465694 + 
IGF2R GRCh37/hg19 chr6 160466772 160466919 + 
IGF2R GRCh37/hg19 chr6 160467525 160467682 + 
IGF2R GRCh37/hg19 chr6 160468186 160468373 + 
IGF2R GRCh37/hg19 chr6 160468819 160468944 + 
IGF2R GRCh37/hg19 chr6 160469402 160469580 + 
IGF2R GRCh37/hg19 chr6 160471500 160471689 + 
IGF2R GRCh37/hg19 chr6 160477451 160477562 + 
IGF2R GRCh37/hg19 chr6 160479050 160479161 + 
10 
 
GENE-EXON Reference Chromosome CHR_Start CHR_End STRAND 
IGF2R GRCh37/hg19 chr6 160479933 160480135 + 
IGF2R GRCh37/hg19 chr6 160481574 160481754 + 
IGF2R GRCh37/hg19 chr6 160482530 160482683 + 
IGF2R GRCh37/hg19 chr6 160482780 160482965 + 
IGF2R GRCh37/hg19 chr6 160483559 160483656 + 
IGF2R GRCh37/hg19 chr6 160484442 160484667 + 
IGF2R GRCh37/hg19 chr6 160485428 160485568 + 
IGF2R GRCh37/hg19 chr6 160485831 160485938 + 
IGF2R GRCh37/hg19 chr6 160489276 160489422 + 
IGF2R GRCh37/hg19 chr6 160490895 160491095 + 
IGF2R GRCh37/hg19 chr6 160492937 160493073 + 
IGF2R GRCh37/hg19 chr6 160493792 160493921 + 
IGF2R GRCh37/hg19 chr6 160494240 160494506 + 
IGF2R GRCh37/hg19 chr6 160494784 160495012 + 
IGF2R GRCh37/hg19 chr6 160496874 160497033 + 
IGF2R GRCh37/hg19 chr6 160499228 160499399 + 
IGF2R GRCh37/hg19 chr6 160500607 160500824 + 
IGF2R GRCh37/hg19 chr6 160501156 160501312 + 
IGF2R GRCh37/hg19 chr6 160504977 160505221 + 
IGF2R GRCh37/hg19 chr6 160506022 160506168 + 
IGF2R GRCh37/hg19 chr6 160509060 160509184 + 
IGF2R GRCh37/hg19 chr6 160510134 160510290 + 
IGF2R GRCh37/hg19 chr6 160510943 160511140 + 
IGF2R GRCh37/hg19 chr6 160517466 160517662 + 
IGF2R GRCh37/hg19 chr6 160523546 160523708 + 
IGF2R GRCh37/hg19 chr6 160524773 160524852 + 
IGF2R GRCh37/hg19 chr6 160525701 160526121 + 
KDM5C GRCh37/hg19 chrX 53221921 53222024 - 
KDM5C GRCh37/hg19 chrX 53222144 53222519 - 
KDM5C GRCh37/hg19 chrX 53222614 53222823 - 
KDM5C GRCh37/hg19 chrX 53222950 53223038 - 
KDM5C GRCh37/hg19 chrX 53223316 53223925 - 
KDM5C GRCh37/hg19 chrX 53224108 53224255 - 
KDM5C GRCh37/hg19 chrX 53224408 53224597 - 
KDM5C GRCh37/hg19 chrX 53225093 53225241 - 
KDM5C GRCh37/hg19 chrX 53225863 53226231 - 
KDM5C GRCh37/hg19 chrX 53226948 53227063 - 
KDM5C GRCh37/hg19 chrX 53227667 53227824 - 
KDM5C GRCh37/hg19 chrX 53227941 53228075 - 
KDM5C GRCh37/hg19 chrX 53228154 53228345 - 
KDM5C GRCh37/hg19 chrX 53230727 53230931 - 
KDM5C GRCh37/hg19 chrX 53231031 53231160 - 
KDM5C GRCh37/hg19 chrX 53239591 53239763 - 
KDM5C GRCh37/hg19 chrX 53239853 53240044 - 
KDM5C GRCh37/hg19 chrX 53240674 53240842 - 
KDM5C GRCh37/hg19 chrX 53240964 53241093 - 
KDM5C GRCh37/hg19 chrX 53243866 53244034 - 
KDM5C GRCh37/hg19 chrX 53244972 53245163 - 
KDM5C GRCh37/hg19 chrX 53245251 53245384 - 
KDM5C GRCh37/hg19 chrX 53246320 53246464 - 
KDM5C GRCh37/hg19 chrX 53246973 53247153 - 
KDM5C GRCh37/hg19 chrX 53247453 53247585 - 
KDM5C GRCh37/hg19 chrX 53250016 53250103 - 
KDM5C GRCh37/hg19 chrX 53253917 53254076 - 
KMT2C GRCh37/hg19 chr7 151833912 151834014 - 
KMT2C GRCh37/hg19 chr7 151835876 151835994 - 
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KMT2C GRCh37/hg19 chr7 151836266 151836349 - 
KMT2C GRCh37/hg19 chr7 151836755 151836881 - 
KMT2C GRCh37/hg19 chr7 151841793 151841971 - 
KMT2C GRCh37/hg19 chr7 151842233 151842385 - 
KMT2C GRCh37/hg19 chr7 151843679 151843825 - 
KMT2C GRCh37/hg19 chr7 151845113 151846242 - 
KMT2C GRCh37/hg19 chr7 151847980 151848097 - 
KMT2C GRCh37/hg19 chr7 151848522 151848671 - 
KMT2C GRCh37/hg19 chr7 151849785 151850044 - 
KMT2C GRCh37/hg19 chr7 151851090 151851236 - 
KMT2C GRCh37/hg19 chr7 151851347 151851535 - 
KMT2C GRCh37/hg19 chr7 151852990 151853147 - 
KMT2C GRCh37/hg19 chr7 151853285 151853436 - 
KMT2C GRCh37/hg19 chr7 151855943 151856162 - 
KMT2C GRCh37/hg19 chr7 151859197 151860916 - 
KMT2C GRCh37/hg19 chr7 151864226 151864468 - 
KMT2C GRCh37/hg19 chr7 151866266 151866339 - 
KMT2C GRCh37/hg19 chr7 151868344 151868432 - 
KMT2C GRCh37/hg19 chr7 151871211 151871332 - 
KMT2C GRCh37/hg19 chr7 151873271 151875100 - 
KMT2C GRCh37/hg19 chr7 151876914 151877216 - 
KMT2C GRCh37/hg19 chr7 151877791 151879684 - 
KMT2C GRCh37/hg19 chr7 151880054 151880246 - 
KMT2C GRCh37/hg19 chr7 151882638 151882721 - 
KMT2C GRCh37/hg19 chr7 151884342 151884566 - 
KMT2C GRCh37/hg19 chr7 151884795 151884937 - 
KMT2C GRCh37/hg19 chr7 151891089 151891218 - 
KMT2C GRCh37/hg19 chr7 151891309 151891351 - 
KMT2C GRCh37/hg19 chr7 151891520 151891658 - 
KMT2C GRCh37/hg19 chr7 151892987 151893101 - 
KMT2C GRCh37/hg19 chr7 151896359 151896549 - 
KMT2C GRCh37/hg19 chr7 151900014 151900154 - 
KMT2C GRCh37/hg19 chr7 151902186 151902315 - 
KMT2C GRCh37/hg19 chr7 151904380 151904518 - 
KMT2C GRCh37/hg19 chr7 151917603 151917825 - 
KMT2C GRCh37/hg19 chr7 151919081 151919156 - 
KMT2C GRCh37/hg19 chr7 151919653 151919772 - 
KMT2C GRCh37/hg19 chr7 151921095 151921269 - 
KMT2C GRCh37/hg19 chr7 151921515 151921706 - 
KMT2C GRCh37/hg19 chr7 151927003 151927117 - 
KMT2C GRCh37/hg19 chr7 151927300 151927411 - 
KMT2C GRCh37/hg19 chr7 151932897 151933023 - 
KMT2C GRCh37/hg19 chr7 151935787 151935916 - 
KMT2C GRCh37/hg19 chr7 151944982 151945710 - 
KMT2C GRCh37/hg19 chr7 151946956 151947043 - 
KMT2C GRCh37/hg19 chr7 151947933 151948056 - 
KMT2C GRCh37/hg19 chr7 151949019 151949180 - 
KMT2C GRCh37/hg19 chr7 151949626 151949805 - 
KMT2C GRCh37/hg19 chr7 151960096 151960220 - 
KMT2C GRCh37/hg19 chr7 151962118 151962299 - 
KMT2C GRCh37/hg19 chr7 151970785 151970957 - 
KMT2C GRCh37/hg19 chr7 152007046 152007165 - 
KMT2C GRCh37/hg19 chr7 152008878 152009036 - 
KMT2C GRCh37/hg19 chr7 152012218 152012428 - 
KMT2C GRCh37/hg19 chr7 152027681 152027829 - 
KMT2C GRCh37/hg19 chr7 152055667 152055765 - 
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KMT2C GRCh37/hg19 chr7 152132706 152132876 - 
MED12 GRCh37/hg19 chrX 70338600 70338708 + 
MED12 GRCh37/hg19 chrX 70339218 70339332 + 
MED12 GRCh37/hg19 chrX 70339531 70339732 + 
MED12 GRCh37/hg19 chrX 70339859 70340025 + 
MED12 GRCh37/hg19 chrX 70340816 70341007 + 
MED12 GRCh37/hg19 chrX 70341172 70341292 + 
MED12 GRCh37/hg19 chrX 70341407 70341671 + 
MED12 GRCh37/hg19 chrX 70342045 70342201 + 
MED12 GRCh37/hg19 chrX 70342353 70342462 + 
MED12 GRCh37/hg19 chrX 70342583 70342729 + 
MED12 GRCh37/hg19 chrX 70342940 70343081 + 
MED12 GRCh37/hg19 chrX 70343439 70343575 + 
MED12 GRCh37/hg19 chrX 70344004 70344243 + 
MED12 GRCh37/hg19 chrX 70344609 70344699 + 
MED12 GRCh37/hg19 chrX 70344821 70345001 + 
MED12 GRCh37/hg19 chrX 70345196 70345350 + 
MED12 GRCh37/hg19 chrX 70345508 70345568 + 
MED12 GRCh37/hg19 chrX 70345881 70346009 + 
MED12 GRCh37/hg19 chrX 70346186 70346339 + 
MED12 GRCh37/hg19 chrX 70346814 70346987 + 
MED12 GRCh37/hg19 chrX 70347181 70347322 + 
MED12 GRCh37/hg19 chrX 70347738 70347975 + 
MED12 GRCh37/hg19 chrX 70348141 70348295 + 
MED12 GRCh37/hg19 chrX 70348443 70348573 + 
MED12 GRCh37/hg19 chrX 70348959 70349070 + 
MED12 GRCh37/hg19 chrX 70349161 70349284 + 
MED12 GRCh37/hg19 chrX 70349525 70349710 + 
MED12 GRCh37/hg19 chrX 70349880 70350069 + 
MED12 GRCh37/hg19 chrX 70351395 70351476 + 
MED12 GRCh37/hg19 chrX 70351918 70352061 + 
MED12 GRCh37/hg19 chrX 70352222 70352393 + 
MED12 GRCh37/hg19 chrX 70352690 70352811 + 
MED12 GRCh37/hg19 chrX 70352968 70353067 + 
MED12 GRCh37/hg19 chrX 70354202 70354321 + 
MED12 GRCh37/hg19 chrX 70354558 70354703 + 
MED12 GRCh37/hg19 chrX 70354937 70355108 + 
MED12 GRCh37/hg19 chrX 70356126 70356510 + 
MED12 GRCh37/hg19 chrX 70356724 70356884 + 
MED12 GRCh37/hg19 chrX 70357032 70357238 + 
MED12 GRCh37/hg19 chrX 70357403 70357490 + 
MED12 GRCh37/hg19 chrX 70357571 70357798 + 
MED12 GRCh37/hg19 chrX 70360480 70360712 + 
MED12 GRCh37/hg19 chrX 70361075 70361225 + 
MED12 GRCh37/hg19 chrX 70361728 70361819 + 
MED12 GRCh37/hg19 chrX 70362020 70362073 + 
MEN1 GRCh37/hg19 chr11 64571801 64572293 - 
MEN1 GRCh37/hg19 chr11 64572501 64572675 - 
MEN1 GRCh37/hg19 chr11 64573102 64573247 - 
MEN1 GRCh37/hg19 chr11 64573699 64573845 - 
MEN1 GRCh37/hg19 chr11 64574478 64574575 - 
MEN1 GRCh37/hg19 chr11 64574646 64574696 - 
MEN1 GRCh37/hg19 chr11 64575019 64575157 - 
MEN1 GRCh37/hg19 chr11 64575358 64575576 - 
MEN1 GRCh37/hg19 chr11 64577117 64577586 - 
MSH2 GRCh37/hg19 chr2 47630326 47630546 + 
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MSH2 GRCh37/hg19 chr2 47635535 47635699 + 
MSH2 GRCh37/hg19 chr2 47637228 47637516 + 
MSH2 GRCh37/hg19 chr2 47639548 47639704 + 
MSH2 GRCh37/hg19 chr2 47641403 47641562 + 
MSH2 GRCh37/hg19 chr2 47643430 47643573 + 
MSH2 GRCh37/hg19 chr2 47656876 47657085 + 
MSH2 GRCh37/hg19 chr2 47672682 47672801 + 
MSH2 GRCh37/hg19 chr2 47690165 47690298 + 
MSH2 GRCh37/hg19 chr2 47693792 47693952 + 
MSH2 GRCh37/hg19 chr2 47698099 47698206 + 
MSH2 GRCh37/hg19 chr2 47702159 47702414 + 
MSH2 GRCh37/hg19 chr2 47703501 47703715 + 
MSH2 GRCh37/hg19 chr2 47705406 47705663 + 
MSH2 GRCh37/hg19 chr2 47707830 47708015 + 
MSH2 GRCh37/hg19 chr2 47709913 47710093 + 
MSH6 GRCh37/hg19 chr2 48010368 48010637 + 
MSH6 GRCh37/hg19 chr2 48018061 48018267 + 
MSH6 GRCh37/hg19 chr2 48023028 48023207 + 
MSH6 GRCh37/hg19 chr2 48025745 48028299 + 
MSH6 GRCh37/hg19 chr2 48030554 48030829 + 
MSH6 GRCh37/hg19 chr2 48032044 48032171 + 
MSH6 GRCh37/hg19 chr2 48032752 48032851 + 
MSH6 GRCh37/hg19 chr2 48033338 48033502 + 
MSH6 GRCh37/hg19 chr2 48033586 48033795 + 
MSH6 GRCh37/hg19 chr2 48033913 48034004 + 
MTOR GRCh37/hg19 chr1 11167537 11167562 - 
MTOR GRCh37/hg19 chr1 11168233 11168348 - 
MTOR GRCh37/hg19 chr1 11169342 11169432 - 
MTOR GRCh37/hg19 chr1 11169701 11169791 - 
MTOR GRCh37/hg19 chr1 11172904 11172979 - 
MTOR GRCh37/hg19 chr1 11174370 11174515 - 
MTOR GRCh37/hg19 chr1 11174865 11174949 - 
MTOR GRCh37/hg19 chr1 11175448 11175530 - 
MTOR GRCh37/hg19 chr1 11177056 11177148 - 
MTOR GRCh37/hg19 chr1 11181298 11181430 - 
MTOR GRCh37/hg19 chr1 11182031 11182188 - 
MTOR GRCh37/hg19 chr1 11184550 11184695 - 
MTOR GRCh37/hg19 chr1 11186674 11186858 - 
MTOR GRCh37/hg19 chr1 11187062 11187206 - 
MTOR GRCh37/hg19 chr1 11187676 11187868 - 
MTOR GRCh37/hg19 chr1 11188056 11188188 - 
MTOR GRCh37/hg19 chr1 11188506 11188614 - 
MTOR GRCh37/hg19 chr1 11188907 11189013 - 
MTOR GRCh37/hg19 chr1 11189790 11189900 - 
MTOR GRCh37/hg19 chr1 11190581 11190839 - 
MTOR GRCh37/hg19 chr1 11193132 11193259 - 
MTOR GRCh37/hg19 chr1 11194403 11194528 - 
MTOR GRCh37/hg19 chr1 11199356 11199497 - 
MTOR GRCh37/hg19 chr1 11199585 11199720 - 
MTOR GRCh37/hg19 chr1 11204700 11204817 - 
MTOR GRCh37/hg19 chr1 11205020 11205107 - 
MTOR GRCh37/hg19 chr1 11206728 11206853 - 
MTOR GRCh37/hg19 chr1 11210178 11210288 - 
MTOR GRCh37/hg19 chr1 11217204 11217353 - 
MTOR GRCh37/hg19 chr1 11227494 11227579 - 
MTOR GRCh37/hg19 chr1 11259310 11259465 - 
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MTOR GRCh37/hg19 chr1 11259593 11259765 - 
MTOR GRCh37/hg19 chr1 11264613 11264765 - 
MTOR GRCh37/hg19 chr1 11269364 11269520 - 
MTOR GRCh37/hg19 chr1 11270866 11270968 - 
MTOR GRCh37/hg19 chr1 11272364 11272536 - 
MTOR GRCh37/hg19 chr1 11272848 11272970 - 
MTOR GRCh37/hg19 chr1 11273451 11273628 - 
MTOR GRCh37/hg19 chr1 11276200 11276296 - 
MTOR GRCh37/hg19 chr1 11288720 11288980 - 
MTOR GRCh37/hg19 chr1 11290977 11291116 - 
MTOR GRCh37/hg19 chr1 11291352 11291496 - 
MTOR GRCh37/hg19 chr1 11292488 11292590 - 
MTOR GRCh37/hg19 chr1 11293450 11293549 - 
MTOR GRCh37/hg19 chr1 11294195 11294327 - 
MTOR GRCh37/hg19 chr1 11297895 11298110 - 
MTOR GRCh37/hg19 chr1 11298454 11298679 - 
MTOR GRCh37/hg19 chr1 11300355 11300609 - 
MTOR GRCh37/hg19 chr1 11301605 11301743 - 
MTOR GRCh37/hg19 chr1 11303166 11303362 - 
MTOR GRCh37/hg19 chr1 11307677 11307795 - 
MTOR GRCh37/hg19 chr1 11307871 11308156 - 
MTOR GRCh37/hg19 chr1 11313891 11314035 - 
MTOR GRCh37/hg19 chr1 11316044 11316254 - 
MTOR GRCh37/hg19 chr1 11316985 11317227 - 
MTOR GRCh37/hg19 chr1 11318537 11318655 - 
MTOR GRCh37/hg19 chr1 11319300 11319471 - 
NF1 GRCh37/hg19 chr17 29422323 29422392 + 
NF1 GRCh37/hg19 chr17 29482996 29483149 + 
NF1 GRCh37/hg19 chr17 29486023 29486116 + 
NF1 GRCh37/hg19 chr17 29490199 29490399 + 
NF1 GRCh37/hg19 chr17 29496904 29497020 + 
NF1 GRCh37/hg19 chr17 29508435 29508512 + 
NF1 GRCh37/hg19 chr17 29508723 29508808 + 
NF1 GRCh37/hg19 chr17 29509521 29509688 + 
NF1 GRCh37/hg19 chr17 29527435 29527618 + 
NF1 GRCh37/hg19 chr17 29528050 29528182 + 
NF1 GRCh37/hg19 chr17 29528424 29528508 + 
NF1 GRCh37/hg19 chr17 29533253 29533394 + 
NF1 GRCh37/hg19 chr17 29541464 29541608 + 
NF1 GRCh37/hg19 chr17 29546018 29546141 + 
NF1 GRCh37/hg19 chr17 29548863 29549013 + 
NF1 GRCh37/hg19 chr17 29550457 29550590 + 
NF1 GRCh37/hg19 chr17 29552108 29552273 + 
NF1 GRCh37/hg19 chr17 29553448 29553707 + 
NF1 GRCh37/hg19 chr17 29554231 29554314 + 
NF1 GRCh37/hg19 chr17 29554536 29554629 + 
NF1 GRCh37/hg19 chr17 29556038 29556488 + 
NF1 GRCh37/hg19 chr17 29556848 29556997 + 
NF1 GRCh37/hg19 chr17 29557273 29557405 + 
NF1 GRCh37/hg19 chr17 29557855 29557948 + 
NF1 GRCh37/hg19 chr17 29559086 29559212 + 
NF1 GRCh37/hg19 chr17 29559713 29559904 + 
NF1 GRCh37/hg19 chr17 29560015 29560236 + 
NF1 GRCh37/hg19 chr17 29562624 29562795 + 
NF1 GRCh37/hg19 chr17 29562931 29563044 + 
NF1 GRCh37/hg19 chr17 29575997 29576142 + 
15 
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NF1 GRCh37/hg19 chr17 29579951 29580023 + 
NF1 GRCh37/hg19 chr17 29585357 29585525 + 
NF1 GRCh37/hg19 chr17 29586045 29586152 + 
NF1 GRCh37/hg19 chr17 29587382 29587538 + 
NF1 GRCh37/hg19 chr17 29588724 29588880 + 
NF1 GRCh37/hg19 chr17 29592242 29592362 + 
NF1 GRCh37/hg19 chr17 29652833 29653275 + 
NF1 GRCh37/hg19 chr17 29654512 29654862 + 
NF1 GRCh37/hg19 chr17 29657309 29657521 + 
NF1 GRCh37/hg19 chr17 29661851 29662054 + 
NF1 GRCh37/hg19 chr17 29663346 29663496 + 
NF1 GRCh37/hg19 chr17 29663648 29663937 + 
NF1 GRCh37/hg19 chr17 29664381 29664605 + 
NF1 GRCh37/hg19 chr17 29664832 29664903 + 
NF1 GRCh37/hg19 chr17 29665038 29665162 + 
NF1 GRCh37/hg19 chr17 29665717 29665828 + 
NF1 GRCh37/hg19 chr17 29667518 29667668 + 
NF1 GRCh37/hg19 chr17 29670022 29670158 + 
NF1 GRCh37/hg19 chr17 29676133 29676274 + 
NF1 GRCh37/hg19 chr17 29677196 29677341 + 
NF1 GRCh37/hg19 chr17 29679270 29679437 + 
NF1 GRCh37/hg19 chr17 29683473 29683605 + 
NF1 GRCh37/hg19 chr17 29683973 29684113 + 
NF1 GRCh37/hg19 chr17 29684282 29684392 + 
NF1 GRCh37/hg19 chr17 29685493 29685645 + 
NF1 GRCh37/hg19 chr17 29685982 29686038 + 
NF1 GRCh37/hg19 chr17 29687500 29687726 + 
NF1 GRCh37/hg19 chr17 29701026 29701178 + 
PBRM1 GRCh37/hg19 chr3 52582074 52582256 - 
PBRM1 GRCh37/hg19 chr3 52584432 52584658 - 
PBRM1 GRCh37/hg19 chr3 52584758 52584838 - 
PBRM1 GRCh37/hg19 chr3 52588735 52588900 - 
PBRM1 GRCh37/hg19 chr3 52595778 52595989 - 
PBRM1 GRCh37/hg19 chr3 52597375 52597514 - 
PBRM1 GRCh37/hg19 chr3 52598061 52598254 - 
PBRM1 GRCh37/hg19 chr3 52610552 52610719 - 
PBRM1 GRCh37/hg19 chr3 52613065 52613220 - 
PBRM1 GRCh37/hg19 chr3 52620436 52620709 - 
PBRM1 GRCh37/hg19 chr3 52621364 52621456 - 
PBRM1 GRCh37/hg19 chr3 52623081 52623276 - 
PBRM1 GRCh37/hg19 chr3 52637532 52637753 - 
PBRM1 GRCh37/hg19 chr3 52643324 52643976 - 
PBRM1 GRCh37/hg19 chr3 52649362 52649477 - 
PBRM1 GRCh37/hg19 chr3 52651273 52651559 - 
PBRM1 GRCh37/hg19 chr3 52661284 52661391 - 
PBRM1 GRCh37/hg19 chr3 52662905 52663056 - 
PBRM1 GRCh37/hg19 chr3 52668613 52668836 - 
PBRM1 GRCh37/hg19 chr3 52675965 52676066 - 
PBRM1 GRCh37/hg19 chr3 52677259 52677364 - 
PBRM1 GRCh37/hg19 chr3 52678715 52678810 - 
PBRM1 GRCh37/hg19 chr3 52682355 52682463 - 
PBRM1 GRCh37/hg19 chr3 52685753 52685831 - 
PBRM1 GRCh37/hg19 chr3 52692210 52692336 - 
PBRM1 GRCh37/hg19 chr3 52696144 52696297 - 
PBRM1 GRCh37/hg19 chr3 52702509 52702666 - 
PBRM1 GRCh37/hg19 chr3 52712511 52712618 - 
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PBRM1 GRCh37/hg19 chr3 52713585 52713732 - 
PDGFRB GRCh37/hg19 chr5 149495321 149495514 - 
PDGFRB GRCh37/hg19 chr5 149497176 149497418 - 
PDGFRB GRCh37/hg19 chr5 149498305 149498420 - 
PDGFRB GRCh37/hg19 chr5 149499025 149499134 - 
PDGFRB GRCh37/hg19 chr5 149499570 149499691 - 
PDGFRB GRCh37/hg19 chr5 149500446 149500578 - 
PDGFRB GRCh37/hg19 chr5 149500762 149500890 - 
PDGFRB GRCh37/hg19 chr5 149501438 149501608 - 
PDGFRB GRCh37/hg19 chr5 149502600 149502769 - 
PDGFRB GRCh37/hg19 chr5 149503808 149503928 - 
PDGFRB GRCh37/hg19 chr5 149504285 149504399 - 
PDGFRB GRCh37/hg19 chr5 149505003 149505145 - 
PDGFRB GRCh37/hg19 chr5 149506078 149506182 - 
PDGFRB GRCh37/hg19 chr5 149509315 149509536 - 
PDGFRB GRCh37/hg19 chr5 149510097 149510230 - 
PDGFRB GRCh37/hg19 chr5 149511537 149511662 - 
PDGFRB GRCh37/hg19 chr5 149512308 149512510 - 
PDGFRB GRCh37/hg19 chr5 149513144 149513328 - 
PDGFRB GRCh37/hg19 chr5 149513439 149513576 - 
PDGFRB GRCh37/hg19 chr5 149514308 149514584 - 
PDGFRB GRCh37/hg19 chr5 149515113 149515446 - 
PDGFRB GRCh37/hg19 chr5 149516566 149516615 - 
PIK3R1 GRCh37/hg19 chr5 67522499 67522842 + 
PIK3R1 GRCh37/hg19 chr5 67569213 67569315 + 
PIK3R1 GRCh37/hg19 chr5 67569762 67569846 + 
PIK3R1 GRCh37/hg19 chr5 67575425 67575566 + 
PIK3R1 GRCh37/hg19 chr5 67576351 67576562 + 
PIK3R1 GRCh37/hg19 chr5 67576750 67576839 + 
PIK3R1 GRCh37/hg19 chr5 67584559 67584584 + 
PIK3R1 GRCh37/hg19 chr5 67586552 67586667 + 
PIK3R1 GRCh37/hg19 chr5 67588082 67588194 + 
PIK3R1 GRCh37/hg19 chr5 67588924 67589032 + 
PIK3R1 GRCh37/hg19 chr5 67589126 67589316 + 
PIK3R1 GRCh37/hg19 chr5 67589532 67589667 + 
PIK3R1 GRCh37/hg19 chr5 67590359 67590511 + 
PIK3R1 GRCh37/hg19 chr5 67590971 67591157 + 
PIK3R1 GRCh37/hg19 chr5 67591243 67591321 + 
PIK3R1 GRCh37/hg19 chr5 67591994 67592174 + 
PIK3R1 GRCh37/hg19 chr5 67593235 67593434 + 
PMS2 GRCh37/hg19 chr7 6013025 6013178 - 
PMS2 GRCh37/hg19 chr7 6017214 6017393 - 
PMS2 GRCh37/hg19 chr7 6018222 6018332 - 
PMS2 GRCh37/hg19 chr7 6022450 6022627 - 
PMS2 GRCh37/hg19 chr7 6026385 6027256 - 
PMS2 GRCh37/hg19 chr7 6029426 6029591 - 
PMS2 GRCh37/hg19 chr7 6031599 6031693 - 
PMS2 GRCh37/hg19 chr7 6035160 6035269 - 
PMS2 GRCh37/hg19 chr7 6036952 6037059 - 
PMS2 GRCh37/hg19 chr7 6038734 6038911 - 
PMS2 GRCh37/hg19 chr7 6042079 6042272 - 
PMS2 GRCh37/hg19 chr7 6043316 6043428 - 
PMS2 GRCh37/hg19 chr7 6043598 6043694 - 
PMS2 GRCh37/hg19 chr7 6045518 6045667 - 
PMS2 GRCh37/hg19 chr7 6048623 6048655 - 
POLK GRCh37/hg19 chr5 74842843 74842987 + 
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POLK GRCh37/hg19 chr5 74848292 74848421 + 
POLK GRCh37/hg19 chr5 74865160 74865322 + 
POLK GRCh37/hg19 chr5 74869558 74869699 + 
POLK GRCh37/hg19 chr5 74872600 74872763 + 
POLK GRCh37/hg19 chr5 74877029 74877278 + 
POLK GRCh37/hg19 chr5 74879113 74879247 + 
POLK GRCh37/hg19 chr5 74880580 74880756 + 
POLK GRCh37/hg19 chr5 74882846 74882888 + 
POLK GRCh37/hg19 chr5 74886164 74886270 + 
POLK GRCh37/hg19 chr5 74889698 74889879 + 
POLK GRCh37/hg19 chr5 74892042 74893008 + 
POLK GRCh37/hg19 chr5 74893567 74893619 + 
POLK GRCh37/hg19 chr5 74893754 74893848 + 
PRKDC GRCh37/hg19 chr8 48686729 48686943 - 
PRKDC GRCh37/hg19 chr8 48689400 48689549 - 
PRKDC GRCh37/hg19 chr8 48690242 48690440 - 
PRKDC GRCh37/hg19 chr8 48691015 48691226 - 
PRKDC GRCh37/hg19 chr8 48691284 48691365 - 
PRKDC GRCh37/hg19 chr8 48691560 48691659 - 
PRKDC GRCh37/hg19 chr8 48694718 48694820 - 
PRKDC GRCh37/hg19 chr8 48694934 48695164 - 
PRKDC GRCh37/hg19 chr8 48696298 48696375 - 
PRKDC GRCh37/hg19 chr8 48697669 48697883 - 
PRKDC GRCh37/hg19 chr8 48701462 48701615 - 
PRKDC GRCh37/hg19 chr8 48701707 48701804 - 
PRKDC GRCh37/hg19 chr8 48706846 48707067 - 
PRKDC GRCh37/hg19 chr8 48710793 48710963 - 
PRKDC GRCh37/hg19 chr8 48711766 48711956 - 
PRKDC GRCh37/hg19 chr8 48713349 48713552 - 
PRKDC GRCh37/hg19 chr8 48715862 48716046 - 
PRKDC GRCh37/hg19 chr8 48719693 48719892 - 
PRKDC GRCh37/hg19 chr8 48730006 48730127 - 
PRKDC GRCh37/hg19 chr8 48731958 48732076 - 
PRKDC GRCh37/hg19 chr8 48733275 48733509 - 
PRKDC GRCh37/hg19 chr8 48734160 48734358 - 
PRKDC GRCh37/hg19 chr8 48736414 48736562 - 
PRKDC GRCh37/hg19 chr8 48739212 48739427 - 
PRKDC GRCh37/hg19 chr8 48740724 48740913 - 
PRKDC GRCh37/hg19 chr8 48743161 48743302 - 
PRKDC GRCh37/hg19 chr8 48744370 48744492 - 
PRKDC GRCh37/hg19 chr8 48746752 48746962 - 
PRKDC GRCh37/hg19 chr8 48748894 48749093 - 
PRKDC GRCh37/hg19 chr8 48749768 48749985 - 
PRKDC GRCh37/hg19 chr8 48751704 48751812 - 
PRKDC GRCh37/hg19 chr8 48752572 48752755 - 
PRKDC GRCh37/hg19 chr8 48761710 48761869 - 
PRKDC GRCh37/hg19 chr8 48761935 48762069 - 
PRKDC GRCh37/hg19 chr8 48765229 48765350 - 
PRKDC GRCh37/hg19 chr8 48766639 48766780 - 
PRKDC GRCh37/hg19 chr8 48767778 48767939 - 
PRKDC GRCh37/hg19 chr8 48769712 48769865 - 
PRKDC GRCh37/hg19 chr8 48771072 48771201 - 
PRKDC GRCh37/hg19 chr8 48771405 48771552 - 
PRKDC GRCh37/hg19 chr8 48772167 48772325 - 
PRKDC GRCh37/hg19 chr8 48773455 48773537 - 
PRKDC GRCh37/hg19 chr8 48774618 48774693 - 
18 
 
GENE-EXON Reference Chromosome CHR_Start CHR_End STRAND 
PRKDC GRCh37/hg19 chr8 48774929 48775107 - 
PRKDC GRCh37/hg19 chr8 48775955 48776143 - 
PRKDC GRCh37/hg19 chr8 48777112 48777329 - 
PRKDC GRCh37/hg19 chr8 48790280 48790417 - 
PRKDC GRCh37/hg19 chr8 48792047 48792224 - 
PRKDC GRCh37/hg19 chr8 48793972 48794086 - 
PRKDC GRCh37/hg19 chr8 48794468 48794663 - 
PRKDC GRCh37/hg19 chr8 48798500 48798713 - 
PRKDC GRCh37/hg19 chr8 48800103 48800271 - 
PRKDC GRCh37/hg19 chr8 48801074 48801216 - 
PRKDC GRCh37/hg19 chr8 48801570 48801788 - 
PRKDC GRCh37/hg19 chr8 48802813 48803046 - 
PRKDC GRCh37/hg19 chr8 48805695 48805952 - 
PRKDC GRCh37/hg19 chr8 48809716 48809859 - 
PRKDC GRCh37/hg19 chr8 48811025 48811134 - 
PRKDC GRCh37/hg19 chr8 48812928 48813032 - 
PRKDC GRCh37/hg19 chr8 48815124 48815360 - 
PRKDC GRCh37/hg19 chr8 48817424 48817541 - 
PRKDC GRCh37/hg19 chr8 48824965 48825127 - 
PRKDC GRCh37/hg19 chr8 48826456 48826629 - 
PRKDC GRCh37/hg19 chr8 48827883 48827983 - 
PRKDC GRCh37/hg19 chr8 48830832 48830948 - 
PRKDC GRCh37/hg19 chr8 48839749 48839918 - 
PRKDC GRCh37/hg19 chr8 48840326 48840455 - 
PRKDC GRCh37/hg19 chr8 48841647 48841743 - 
PRKDC GRCh37/hg19 chr8 48842408 48842577 - 
PRKDC GRCh37/hg19 chr8 48843227 48843352 - 
PRKDC GRCh37/hg19 chr8 48845575 48845737 - 
PRKDC GRCh37/hg19 chr8 48846520 48846655 - 
PRKDC GRCh37/hg19 chr8 48847564 48847623 - 
PRKDC GRCh37/hg19 chr8 48848287 48848465 - 
PRKDC GRCh37/hg19 chr8 48848908 48849082 - 
PRKDC GRCh37/hg19 chr8 48852106 48852262 - 
PRKDC GRCh37/hg19 chr8 48855764 48855931 - 
PRKDC GRCh37/hg19 chr8 48856408 48856448 - 
PRKDC GRCh37/hg19 chr8 48856529 48856594 - 
PRKDC GRCh37/hg19 chr8 48866175 48866284 - 
PRKDC GRCh37/hg19 chr8 48866362 48866484 - 
PRKDC GRCh37/hg19 chr8 48866893 48867011 - 
PRKDC GRCh37/hg19 chr8 48868429 48868513 - 
PRKDC GRCh37/hg19 chr8 48869726 48869828 - 
PRKDC GRCh37/hg19 chr8 48869910 48869996 - 
PRKDC GRCh37/hg19 chr8 48872528 48872691 - 
PTCH1 GRCh37/hg19 chr9 98209189 98209738 - 
PTCH1 GRCh37/hg19 chr9 98211346 98211610 - 
PTCH1 GRCh37/hg19 chr9 98212118 98212227 - 
PTCH1 GRCh37/hg19 chr9 98215755 98215907 - 
PTCH1 GRCh37/hg19 chr9 98218553 98218700 - 
PTCH1 GRCh37/hg19 chr9 98220290 98220580 - 
PTCH1 GRCh37/hg19 chr9 98221877 98222070 - 
PTCH1 GRCh37/hg19 chr9 98224133 98224285 - 
PTCH1 GRCh37/hg19 chr9 98229393 98229712 - 
PTCH1 GRCh37/hg19 chr9 98231028 98231440 - 
PTCH1 GRCh37/hg19 chr9 98232090 98232218 - 
PTCH1 GRCh37/hg19 chr9 98238311 98238446 - 
PTCH1 GRCh37/hg19 chr9 98239036 98239144 - 
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PTCH1 GRCh37/hg19 chr9 98239824 98239989 - 
PTCH1 GRCh37/hg19 chr9 98240332 98240473 - 
PTCH1 GRCh37/hg19 chr9 98241277 98241434 - 
PTCH1 GRCh37/hg19 chr9 98242246 98242377 - 
PTCH1 GRCh37/hg19 chr9 98242667 98242875 - 
PTCH1 GRCh37/hg19 chr9 98244226 98244327 - 
PTCH1 GRCh37/hg19 chr9 98244411 98244490 - 
PTCH1 GRCh37/hg19 chr9 98247962 98248161 - 
PTCH1 GRCh37/hg19 chr9 98268684 98268886 - 
PTCH1 GRCh37/hg19 chr9 98270438 98270648 - 
PTCH1 GRCh37/hg19 chr9 98278746 98278758 - 
PTCH1 GRCh37/hg19 chr9 98278900 98279107 - 
RAC1 GRCh37/hg19 chr7 6414362 6414406 + 
RAC1 GRCh37/hg19 chr7 6426838 6426919 + 
RAC1 GRCh37/hg19 chr7 6431550 6431677 + 
RAC1 GRCh37/hg19 chr7 6438288 6438354 + 
RAC1 GRCh37/hg19 chr7 6439752 6439824 + 
RAC1 GRCh37/hg19 chr7 6441494 6441663 + 
RAC1 GRCh37/hg19 chr7 6441942 6442082 + 
RAD50 GRCh37/hg19 chr5 131893012 131893150 + 
RAD50 GRCh37/hg19 chr5 131894971 131895064 + 
RAD50 GRCh37/hg19 chr5 131911464 131911625 + 
RAD50 GRCh37/hg19 chr5 131915004 131915199 + 
RAD50 GRCh37/hg19 chr5 131915549 131915763 + 
RAD50 GRCh37/hg19 chr5 131923249 131923387 + 
RAD50 GRCh37/hg19 chr5 131923611 131923786 + 
RAD50 GRCh37/hg19 chr5 131924374 131924577 + 
RAD50 GRCh37/hg19 chr5 131925318 131925534 + 
RAD50 GRCh37/hg19 chr5 131926911 131927103 + 
RAD50 GRCh37/hg19 chr5 131927564 131927731 + 
RAD50 GRCh37/hg19 chr5 131930556 131930741 + 
RAD50 GRCh37/hg19 chr5 131931260 131931507 + 
RAD50 GRCh37/hg19 chr5 131938987 131939186 + 
RAD50 GRCh37/hg19 chr5 131939607 131939743 + 
RAD50 GRCh37/hg19 chr5 131940493 131940696 + 
RAD50 GRCh37/hg19 chr5 131944302 131944422 + 
RAD50 GRCh37/hg19 chr5 131944804 131944906 + 
RAD50 GRCh37/hg19 chr5 131944970 131945093 + 
RAD50 GRCh37/hg19 chr5 131951690 131951827 + 
RAD50 GRCh37/hg19 chr5 131953757 131953991 + 
RAD50 GRCh37/hg19 chr5 131972802 131972897 + 
RAD50 GRCh37/hg19 chr5 131973768 131973920 + 
RAD50 GRCh37/hg19 chr5 131976359 131976502 + 
RAD50 GRCh37/hg19 chr5 131977865 131978061 + 
RIT1 GRCh37/hg19 chr1 155870174 155870414 - 
RIT1 GRCh37/hg19 chr1 155874097 155874298 - 
RIT1 GRCh37/hg19 chr1 155874517 155874600 - 
RIT1 GRCh37/hg19 chr1 155880236 155880302 - 
RIT1 GRCh37/hg19 chr1 155880442 155880600 - 
RIT1 GRCh37/hg19 chr1 155880664 155880681 - 
RUNX1 GRCh37/hg19 chr21 36164427 36164912 - 
RUNX1 GRCh37/hg19 chr21 36171593 36171764 - 
RUNX1 GRCh37/hg19 chr21 36193960 36193998 - 
RUNX1 GRCh37/hg19 chr21 36206702 36206903 - 
RUNX1 GRCh37/hg19 chr21 36231766 36231880 - 
RUNX1 GRCh37/hg19 chr21 36252849 36253015 - 
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RUNX1 GRCh37/hg19 chr21 36259135 36259414 - 
RUNX1 GRCh37/hg19 chr21 36265217 36265265 - 
RUNX1 GRCh37/hg19 chr21 36421134 36421201 - 
RUNX3 GRCh37/hg19 chr1 25228608 25229162 - 
RUNX3 GRCh37/hg19 chr1 25233745 25233913 - 
RUNX3 GRCh37/hg19 chr1 25245726 25245840 - 
RUNX3 GRCh37/hg19 chr1 25254060 25254226 - 
RUNX3 GRCh37/hg19 chr1 25256073 25256364 - 
RUNX3 GRCh37/hg19 chr1 25291000 25291067 - 
SDHA GRCh37/hg19 chr5 218466 218538 + 
SDHA GRCh37/hg19 chr5 223592 223688 + 
SDHA GRCh37/hg19 chr5 224470 224641 + 
SDHA GRCh37/hg19 chr5 225529 225682 + 
SDHA GRCh37/hg19 chr5 225993 226167 + 
SDHA GRCh37/hg19 chr5 228295 228453 + 
SDHA GRCh37/hg19 chr5 230986 231120 + 
SDHA GRCh37/hg19 chr5 233587 233765 + 
SDHA GRCh37/hg19 chr5 235254 235459 + 
SDHA GRCh37/hg19 chr5 236538 236719 + 
SDHA GRCh37/hg19 chr5 240468 240596 + 
SDHA GRCh37/hg19 chr5 251102 251223 + 
SDHA GRCh37/hg19 chr5 251448 251588 + 
SDHA GRCh37/hg19 chr5 254503 254626 + 
SDHA GRCh37/hg19 chr5 256444 256540 + 
SDHB GRCh37/hg19 chr1 17345371 17345458 - 
SDHB GRCh37/hg19 chr1 17349098 17349230 - 
SDHB GRCh37/hg19 chr1 17350463 17350574 - 
SDHB GRCh37/hg19 chr1 17354239 17354365 - 
SDHB GRCh37/hg19 chr1 17355090 17355236 - 
SDHB GRCh37/hg19 chr1 17359550 17359645 - 
SDHB GRCh37/hg19 chr1 17371251 17371388 - 
SDHB GRCh37/hg19 chr1 17380438 17380519 - 
SDHC GRCh37/hg19 chr1 161284191 161284220 + 
SDHC GRCh37/hg19 chr1 161293399 161293465 + 
SDHC GRCh37/hg19 chr1 161298181 161298292 + 
SDHC GRCh37/hg19 chr1 161310379 161310450 + 
SDHC GRCh37/hg19 chr1 161326462 161326635 + 
SDHC GRCh37/hg19 chr1 161332114 161332335 + 
SDHD GRCh37/hg19 chr11 111957627 111957688 + 
SDHD GRCh37/hg19 chr11 111958576 111958702 + 
SDHD GRCh37/hg19 chr11 111959586 111959740 + 
SDHD GRCh37/hg19 chr11 111963799 111963926 + 
SDHD GRCh37/hg19 chr11 111965524 111965699 + 
SETD2 GRCh37/hg19 chr3 47058578 47058749 - 
SETD2 GRCh37/hg19 chr3 47059123 47059234 - 
SETD2 GRCh37/hg19 chr3 47061245 47061335 - 
SETD2 GRCh37/hg19 chr3 47079151 47079272 - 
SETD2 GRCh37/hg19 chr3 47084046 47084195 - 
SETD2 GRCh37/hg19 chr3 47087972 47088116 - 
SETD2 GRCh37/hg19 chr3 47098306 47098985 - 
SETD2 GRCh37/hg19 chr3 47103648 47103841 - 
SETD2 GRCh37/hg19 chr3 47108555 47108613 - 
SETD2 GRCh37/hg19 chr3 47125205 47125877 - 
SETD2 GRCh37/hg19 chr3 47127680 47127809 - 
SETD2 GRCh37/hg19 chr3 47129598 47129742 - 
SETD2 GRCh37/hg19 chr3 47139440 47139576 - 
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SETD2 GRCh37/hg19 chr3 47142943 47143050 - 
SETD2 GRCh37/hg19 chr3 47144831 47144918 - 
SETD2 GRCh37/hg19 chr3 47147482 47147615 - 
SETD2 GRCh37/hg19 chr3 47155361 47155499 - 
SETD2 GRCh37/hg19 chr3 47158108 47158249 - 
SETD2 GRCh37/hg19 chr3 47161667 47166043 - 
SETD2 GRCh37/hg19 chr3 47168133 47168158 - 
SETD2 GRCh37/hg19 chr3 47205339 47205419 - 
SMAD2 GRCh37/hg19 chr18 45368193 45368326 - 
SMAD2 GRCh37/hg19 chr18 45371706 45371860 - 
SMAD2 GRCh37/hg19 chr18 45372029 45372176 - 
SMAD2 GRCh37/hg19 chr18 45374841 45375063 - 
SMAD2 GRCh37/hg19 chr18 45377640 45377703 - 
SMAD2 GRCh37/hg19 chr18 45391425 45391509 - 
SMAD2 GRCh37/hg19 chr18 45394689 45394833 - 
SMAD2 GRCh37/hg19 chr18 45395609 45395812 - 
SMAD2 GRCh37/hg19 chr18 45396841 45396940 - 
SMAD2 GRCh37/hg19 chr18 45422887 45423132 - 
SMAD3 GRCh37/hg19 chr15 67358488 67358703 + 
SMAD3 GRCh37/hg19 chr15 67430360 67430443 + 
SMAD3 GRCh37/hg19 chr15 67457228 67457431 + 
SMAD3 GRCh37/hg19 chr15 67457586 67457727 + 
SMAD3 GRCh37/hg19 chr15 67459112 67459196 + 
SMAD3 GRCh37/hg19 chr15 67462887 67462947 + 
SMAD3 GRCh37/hg19 chr15 67473574 67473796 + 
SMAD3 GRCh37/hg19 chr15 67477060 67477207 + 
SMAD3 GRCh37/hg19 chr15 67479698 67479852 + 
SMAD3 GRCh37/hg19 chr15 67482746 67482879 + 
SMAD4 GRCh37/hg19 chr18 48573412 48573670 + 
SMAD4 GRCh37/hg19 chr18 48575051 48575235 + 
SMAD4 GRCh37/hg19 chr18 48575660 48575699 + 
SMAD4 GRCh37/hg19 chr18 48581146 48581368 + 
SMAD4 GRCh37/hg19 chr18 48584490 48584619 + 
SMAD4 GRCh37/hg19 chr18 48584705 48584831 + 
SMAD4 GRCh37/hg19 chr18 48586231 48586291 + 
SMAD4 GRCh37/hg19 chr18 48591788 48591981 + 
SMAD4 GRCh37/hg19 chr18 48593384 48593562 + 
SMAD4 GRCh37/hg19 chr18 48603003 48603151 + 
SMAD4 GRCh37/hg19 chr18 48604621 48604842 + 
SNX31 GRCh37/hg19 chr8 101586088 101586193 - 
SNX31 GRCh37/hg19 chr8 101589242 101589308 - 
SNX31 GRCh37/hg19 chr8 101596334 101596421 - 
SNX31 GRCh37/hg19 chr8 101601089 101601212 - 
SNX31 GRCh37/hg19 chr8 101608862 101609075 - 
SNX31 GRCh37/hg19 chr8 101612572 101612674 - 
SNX31 GRCh37/hg19 chr8 101620717 101620796 - 
SNX31 GRCh37/hg19 chr8 101624223 101624320 - 
SNX31 GRCh37/hg19 chr8 101625218 101625318 - 
SNX31 GRCh37/hg19 chr8 101629843 101629963 - 
SNX31 GRCh37/hg19 chr8 101642550 101642624 - 
SNX31 GRCh37/hg19 chr8 101648120 101648244 - 
SNX31 GRCh37/hg19 chr8 101661497 101661581 - 
SNX31 GRCh37/hg19 chr8 101661672 101661747 - 
SPOP GRCh37/hg19 chr17 47677735 47677889 - 
SPOP GRCh37/hg19 chr17 47679222 47679374 - 
SPOP GRCh37/hg19 chr17 47684607 47684739 - 
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SPOP GRCh37/hg19 chr17 47685231 47685296 - 
SPOP GRCh37/hg19 chr17 47688637 47688824 - 
SPOP GRCh37/hg19 chr17 47696338 47696475 - 
SPOP GRCh37/hg19 chr17 47696591 47696752 - 
SPOP GRCh37/hg19 chr17 47699303 47699434 - 
SPOP GRCh37/hg19 chr17 47700090 47700177 - 
T GRCh37/hg19 chr6 166571798 166572081 - 
T GRCh37/hg19 chr6 166574320 166574459 - 
T GRCh37/hg19 chr6 166575930 166576113 - 
T GRCh37/hg19 chr6 166578088 166578159 - 
T GRCh37/hg19 chr6 166578283 166578354 - 
T GRCh37/hg19 chr6 166579189 166579333 - 
T GRCh37/hg19 chr6 166580075 166580349 - 
T GRCh37/hg19 chr6 166580869 166581084 - 
TBX3 GRCh37/hg19 chr12 115109641 115110112 - 
TBX3 GRCh37/hg19 chr12 115111965 115112645 - 
TBX3 GRCh37/hg19 chr12 115114113 115114280 - 
TBX3 GRCh37/hg19 chr12 115115380 115115466 - 
TBX3 GRCh37/hg19 chr12 115117305 115117461 - 
TBX3 GRCh37/hg19 chr12 115117713 115117782 - 
TBX3 GRCh37/hg19 chr12 115118679 115118956 - 
TBX3 GRCh37/hg19 chr12 115120612 115121010 - 
TERT GRCh37/hg19 chr5 1253838 1253951 - 
TERT GRCh37/hg19 chr5 1254478 1254625 - 
TERT GRCh37/hg19 chr5 1255397 1255531 - 
TERT GRCh37/hg19 chr5 1258708 1258779 - 
TERT GRCh37/hg19 chr5 1260584 1260720 - 
TERT GRCh37/hg19 chr5 1264514 1264712 - 
TERT GRCh37/hg19 chr5 1266574 1266655 - 
TERT GRCh37/hg19 chr5 1268630 1268753 - 
TERT GRCh37/hg19 chr5 1271229 1271324 - 
TERT GRCh37/hg19 chr5 1272295 1272400 - 
TERT GRCh37/hg19 chr5 1278751 1278916 - 
TERT GRCh37/hg19 chr5 1279401 1279590 - 
TERT GRCh37/hg19 chr5 1280268 1280458 - 
TERT GRCh37/hg19 chr5 1282539 1282744 - 
TERT GRCh37/hg19 chr5 1293423 1294786 - 
TERT GRCh37/hg19 chr5 1294881 1295109 - 
TGFBR2 GRCh37/hg19 chr3 30648371 30648474 + 
TGFBR2 GRCh37/hg19 chr3 30664686 30664770 + 
TGFBR2 GRCh37/hg19 chr3 30686234 30686412 + 
TGFBR2 GRCh37/hg19 chr3 30691757 30691957 + 
TGFBR2 GRCh37/hg19 chr3 30713125 30713934 + 
TGFBR2 GRCh37/hg19 chr3 30715592 30715743 + 
TGFBR2 GRCh37/hg19 chr3 30729871 30730008 + 
TGFBR2 GRCh37/hg19 chr3 30732907 30733096 + 
TNF GRCh37/hg19 chr6 31543514 31543709 + 
TNF GRCh37/hg19 chr6 31544306 31544361 + 
TNF GRCh37/hg19 chr6 31544539 31544596 + 
TNF GRCh37/hg19 chr6 31544888 31545319 + 
TSC1 GRCh37/hg19 chr9 135771617 135772146 - 
TSC1 GRCh37/hg19 chr9 135772566 135772737 - 
TSC1 GRCh37/hg19 chr9 135772805 135773002 - 
TSC1 GRCh37/hg19 chr9 135776097 135776229 - 
TSC1 GRCh37/hg19 chr9 135776971 135777091 - 
TSC1 GRCh37/hg19 chr9 135777987 135778179 - 
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TSC1 GRCh37/hg19 chr9 135779033 135779209 - 
TSC1 GRCh37/hg19 chr9 135779793 135779846 - 
TSC1 GRCh37/hg19 chr9 135780963 135781531 - 
TSC1 GRCh37/hg19 chr9 135782113 135782227 - 
TSC1 GRCh37/hg19 chr9 135782683 135782762 - 
TSC1 GRCh37/hg19 chr9 135785953 135786084 - 
TSC1 GRCh37/hg19 chr9 135786384 135786505 - 
TSC1 GRCh37/hg19 chr9 135786835 135786960 - 
TSC1 GRCh37/hg19 chr9 135787664 135787849 - 
TSC1 GRCh37/hg19 chr9 135796745 135796828 - 
TSC1 GRCh37/hg19 chr9 135797201 135797365 - 
TSC1 GRCh37/hg19 chr9 135798730 135798884 - 
TSC1 GRCh37/hg19 chr9 135800969 135801131 - 
TSC1 GRCh37/hg19 chr9 135802583 135802696 - 
TSC1 GRCh37/hg19 chr9 135804149 135804264 - 
TSC2 GRCh37/hg19 chr16 2098612 2098759 + 
TSC2 GRCh37/hg19 chr16 2100396 2100492 + 
TSC2 GRCh37/hg19 chr16 2103338 2103458 + 
TSC2 GRCh37/hg19 chr16 2104292 2104446 + 
TSC2 GRCh37/hg19 chr16 2105398 2105525 + 
TSC2 GRCh37/hg19 chr16 2106192 2106250 + 
TSC2 GRCh37/hg19 chr16 2106640 2106775 + 
TSC2 GRCh37/hg19 chr16 2107101 2107184 + 
TSC2 GRCh37/hg19 chr16 2108743 2108879 + 
TSC2 GRCh37/hg19 chr16 2110666 2110819 + 
TSC2 GRCh37/hg19 chr16 2111867 2112014 + 
TSC2 GRCh37/hg19 chr16 2112493 2112606 + 
TSC2 GRCh37/hg19 chr16 2112968 2113059 + 
TSC2 GRCh37/hg19 chr16 2114268 2114433 + 
TSC2 GRCh37/hg19 chr16 2115515 2115641 + 
TSC2 GRCh37/hg19 chr16 2120452 2120584 + 
TSC2 GRCh37/hg19 chr16 2121506 2121622 + 
TSC2 GRCh37/hg19 chr16 2121780 2121940 + 
TSC2 GRCh37/hg19 chr16 2122237 2122369 + 
TSC2 GRCh37/hg19 chr16 2122845 2122989 + 
TSC2 GRCh37/hg19 chr16 2124196 2124395 + 
TSC2 GRCh37/hg19 chr16 2125795 2125898 + 
TSC2 GRCh37/hg19 chr16 2126064 2126176 + 
TSC2 GRCh37/hg19 chr16 2126487 2126591 + 
TSC2 GRCh37/hg19 chr16 2127594 2127732 + 
TSC2 GRCh37/hg19 chr16 2129028 2129202 + 
TSC2 GRCh37/hg19 chr16 2129272 2129434 + 
TSC2 GRCh37/hg19 chr16 2129553 2129675 + 
TSC2 GRCh37/hg19 chr16 2130161 2130383 + 
TSC2 GRCh37/hg19 chr16 2131591 2131804 + 
TSC2 GRCh37/hg19 chr16 2132432 2132510 + 
TSC2 GRCh37/hg19 chr16 2133691 2133822 + 
TSC2 GRCh37/hg19 chr16 2134224 2134721 + 
TSC2 GRCh37/hg19 chr16 2134947 2135032 + 
TSC2 GRCh37/hg19 chr16 2135226 2135328 + 
TSC2 GRCh37/hg19 chr16 2136189 2136385 + 
TSC2 GRCh37/hg19 chr16 2136728 2136877 + 
TSC2 GRCh37/hg19 chr16 2137859 2137947 + 
TSC2 GRCh37/hg19 chr16 2138044 2138145 + 
TSC2 GRCh37/hg19 chr16 2138223 2138331 + 
TSC2 GRCh37/hg19 chr16 2138442 2138616 + 
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TXNRD3 GRCh37/hg19 chr3 126326743 126326821 - 
TXNRD3 GRCh37/hg19 chr3 126327337 126327481 - 
TXNRD3 GRCh37/hg19 chr3 126329875 126329980 - 
TXNRD3 GRCh37/hg19 chr3 126334193 126334310 - 
TXNRD3 GRCh37/hg19 chr3 126340580 126340746 - 
TXNRD3 GRCh37/hg19 chr3 126341302 126341388 - 
TXNRD3 GRCh37/hg19 chr3 126348217 126348319 - 
TXNRD3 GRCh37/hg19 chr3 126349550 126349785 - 
TXNRD3 GRCh37/hg19 chr3 126350602 126350727 - 
TXNRD3 GRCh37/hg19 chr3 126352747 126352899 - 
TXNRD3 GRCh37/hg19 chr3 126360870 126360999 - 
TXNRD3 GRCh37/hg19 chr3 126362819 126362901 - 
TXNRD3 GRCh37/hg19 chr3 126363135 126363249 - 
TXNRD3 GRCh37/hg19 chr3 126364949 126365068 - 
TXNRD3 GRCh37/hg19 chr3 126366074 126366144 - 
TXNRD3 GRCh37/hg19 chr3 126373586 126373838 - 
VHL GRCh37/hg19 chr3 10183527 10183876 + 
VHL GRCh37/hg19 chr3 10188193 10188325 + 
VHL GRCh37/hg19 chr3 10191466 10191654 + 
WT1 GRCh37/hg19 chr11 32410599 32410730 + 
WT1 GRCh37/hg19 chr11 32413513 32413615 + 
WT1 GRCh37/hg19 chr11 32414207 32414306 + 
WT1 GRCh37/hg19 chr11 32417798 32417958 + 
WT1 GRCh37/hg19 chr11 32421489 32421595 + 
WT1 GRCh37/hg19 chr11 32438031 32438091 + 
WT1 GRCh37/hg19 chr11 32439118 32439205 + 
WT1 GRCh37/hg19 chr11 32449497 32449609 + 
WT1 GRCh37/hg19 chr11 32450038 32450170 + 
WT1 GRCh37/hg19 chr11 32452071 32452090 + 
WT1 GRCh37/hg19 chr11 32456241 32456896 + 
MPL_10 GRCh37/hg19 chr1 43814934 43815030 + 
NRAS_4 GRCh37/hg19 chr1 115252190 115252349 - 
NRAS_3 GRCh37/hg19 chr1 115256421 115256599 - 
NRAS_2 GRCh37/hg19 chr1 115258671 115258798 - 
DDR2_10 GRCh37/hg19 chr1 162740092 162740302 + 
DDR2_11 GRCh37/hg19 chr1 162741814 162742037 + 
DDR2_12 GRCh37/hg19 chr1 162743259 162743386 + 
DDR2_13 GRCh37/hg19 chr1 162745442 162745633 + 
DDR2_14 GRCh37/hg19 chr1 162745926 162746160 + 
DDR2_15 GRCh37/hg19 chr1 162748370 162748519 + 
DDR2_16 GRCh37/hg19 chr1 162749902 162750022 + 
RET_10 GRCh37/hg19 chr10 43609004 43609123 + 
RET_11 GRCh37/hg19 chr10 43609928 43610184 + 
RET_13 GRCh37/hg19 chr10 43613821 43613928 + 
RET_15 GRCh37/hg19 chr10 43615529 43615651 + 
RET_16 GRCh37/hg19 chr10 43617394 43617464 + 
PTEN_1 GRCh37/hg19 chr10 89624208 89624305 + 
PTEN_3 GRCh37/hg19 chr10 89685270 89685314 + 
PTEN_5 GRCh37/hg19 chr10 89692770 89693008 + 
PTEN_6 GRCh37/hg19 chr10 89711875 89712016 + 
PTEN_7 GRCh37/hg19 chr10 89717610 89717776 + 
PTEN_8 GRCh37/hg19 chr10 89720651 89720875 + 
PTEN_9 GRCh37/hg19 chr10 89725044 89725224 + 
FGFR2_15 GRCh37/hg19 chr10 123246868 123246938 - 
FGFR2_14 GRCh37/hg19 chr10 123247505 123247627 - 
FGFR2_13 GRCh37/hg19 chr10 123256046 123256236 - 
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FGFR2_12 GRCh37/hg19 chr10 123258009 123258119 - 
FGFR2_11 GRCh37/hg19 chr10 123260340 123260461 - 
FGFR2_10 GRCh37/hg19 chr10 123263304 123263455 - 
FGFR2_9 GRCh37/hg19 chr10 123274631 123274833 - 
FGFR2_8 GRCh37/hg19 chr10 123276833 123276977 - 
FGFR2_7 GRCh37/hg19 chr10 123279493 123279683 - 
HRAS_4 GRCh37/hg19 chr11 533453 533612 - 
HRAS_3 GRCh37/hg19 chr11 533766 533944 - 
HRAS_2 GRCh37/hg19 chr11 534212 534375 - 
ATM_8 GRCh37/hg19 chr11 108117691 108117854 + 
ATM_9 GRCh37/hg19 chr11 108119660 108119829 + 
ATM_12 GRCh37/hg19 chr11 108123544 108123639 + 
ATM_17 GRCh37/hg19 chr11 108137898 108138069 + 
ATM_26 GRCh37/hg19 chr11 108154954 108155200 + 
ATM_34 GRCh37/hg19 chr11 108170441 108170612 + 
ATM_35 GRCh37/hg19 chr11 108172375 108172516 + 
ATM_36 GRCh37/hg19 chr11 108173580 108173756 + 
ATM_39 GRCh37/hg19 chr11 108180887 108181042 + 
ATM_50 GRCh37/hg19 chr11 108200941 108201148 + 
ATM_54 GRCh37/hg19 chr11 108204613 108204695 + 
ATM_55 GRCh37/hg19 chr11 108205696 108205836 + 
ATM_56 GRCh37/hg19 chr11 108206572 108206688 + 
ATM_59 GRCh37/hg19 chr11 108218006 108218092 + 
ATM_61 GRCh37/hg19 chr11 108225538 108225601 + 
ATM_63 GRCh37/hg19 chr11 108236052 108236232 + 
KRAS_4 GRCh37/hg19 chr12 25378548 25378707 - 
KRAS_3 GRCh37/hg19 chr12 25380168 25380346 - 
KRAS_2 GRCh37/hg19 chr12 25398208 25398329 - 
ARID2_15 GRCh37/hg19 chr12 46243819 46246679 + 
PTPN11_3 GRCh37/hg19 chr12 112888122 112888316 + 
PTPN11_13 GRCh37/hg19 chr12 112926828 112926979 + 
HNF1A_3 GRCh37/hg19 chr12 121431323 121431509 + 
HNF1A_4 GRCh37/hg19 chr12 121431967 121432208 + 
FLT3_20 GRCh37/hg19 chr13 28592604 28592726 - 
FLT3_16 GRCh37/hg19 chr13 28602315 28602425 - 
FLT3_14 GRCh37/hg19 chr13 28608219 28608351 - 
FLT3_11 GRCh37/hg19 chr13 28610072 28610180 - 
RB1_4 GRCh37/hg19 chr13 48919216 48919335 + 
RB1_6 GRCh37/hg19 chr13 48923092 48923159 + 
RB1_10 GRCh37/hg19 chr13 48941630 48941739 + 
RB1_11 GRCh37/hg19 chr13 48942663 48942740 + 
RB1_14 GRCh37/hg19 chr13 48953730 48953786 + 
RB1_17 GRCh37/hg19 chr13 48955383 48955579 + 
RB1_18 GRCh37/hg19 chr13 49027129 49027247 + 
RB1_20 GRCh37/hg19 chr13 49033824 49033969 + 
RB1_21 GRCh37/hg19 chr13 49037867 49037971 + 
RB1_22 GRCh37/hg19 chr13 49039134 49039247 + 
AKT_5 GRCh37/hg19 chr14 105241413 105241544 - 
AKT_2 GRCh37/hg19 chr14 105246425 105246553 - 
MEK1_2 GRCh37/hg19 chr15 66727365 66727575 + 
MEK1_3 GRCh37/hg19 chr15 66729084 66729230 + 
MEK1_4 GRCh37/hg19 chr15 66735618 66735695 + 
MEK1_5 GRCh37/hg19 chr15 66736994 66737045 + 
MEK1_6 GRCh37/hg19 chr15 66774093 66774217 + 
MEK1_7 GRCh37/hg19 chr15 66777328 66777529 + 
MEK1_8 GRCh37/hg19 chr15 66779566 66779630 + 
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MEK1_9 GRCh37/hg19 chr15 66781553 66781614 + 
MEK1_10 GRCh37/hg19 chr15 66782056 66782101 + 
MEK1_11 GRCh37/hg19 chr15 66782840 66782959 + 
IDH2_4 GRCh37/hg19 chr15 90631819 90631979 - 
CDH1_3 GRCh37/hg19 chr16 68835573 68835796 + 
CDH1_8 GRCh37/hg19 chr16 68846038 68846166 + 
CDH1_9 GRCh37/hg19 chr16 68847216 68847398 + 
TP53_10 GRCh37/hg19 chr17 7573927 7574033 - 
TP53_9 GRCh37/hg19 chr17 7576853 7576926 - 
TP53_8 GRCh37/hg19 chr17 7577019 7577155 - 
TP53_7 GRCh37/hg19 chr17 7577499 7577608 - 
TP53_6 GRCh37/hg19 chr17 7578177 7578289 - 
TP53_5 GRCh37/hg19 chr17 7578371 7578554 - 
TP53_4 GRCh37/hg19 chr17 7579312 7579590 - 
TP53_2 GRCh37/hg19 chr17 7579839 7579940 - 
MEK4_3 GRCh37/hg19 chr17 11958206 11958308 + 
MEK4_4 GRCh37/hg19 chr17 11984673 11984847 + 
MEK4_5 GRCh37/hg19 chr17 11998892 11999011 + 
MEK4_6 GRCh37/hg19 chr17 12011107 12011226 + 
MEK4_7 GRCh37/hg19 chr17 12013692 12013743 + 
MEK4_8 GRCh37/hg19 chr17 12016550 12016677 + 
MEK4_9 GRCh37/hg19 chr17 12028611 12028688 + 
MEK4_10 GRCh37/hg19 chr17 12032456 12032604 + 
HER2_17 GRCh37/hg19 chr17 37879572 37879710 + 
HER2_18 GRCh37/hg19 chr17 37879791 37879913 + 
HER2_19 GRCh37/hg19 chr17 37880165 37880263 + 
HER2_20 GRCh37/hg19 chr17 37880979 37881164 + 
HER2_21 GRCh37/hg19 chr17 37881302 37881457 + 
HER2_22 GRCh37/hg19 chr17 37881580 37881655 + 
HER2_23 GRCh37/hg19 chr17 37881960 37882106 + 
LKB1_1 GRCh37/hg19 chr19 1206880 1207202 + 
LKB1_4 GRCh37/hg19 chr19 1220372 1220504 + 
LKB1_5 GRCh37/hg19 chr19 1220580 1220716 + 
LKB1_6 GRCh37/hg19 chr19 1221212 1221339 + 
LKB1_8 GRCh37/hg19 chr19 1222984 1223171 + 
GNA11_4 GRCh37/hg19 chr19 3114942 3115070 + 
GNA11_5 GRCh37/hg19 chr19 3118922 3119051 + 
JAK3_15 GRCh37/hg19 chr19 17945661 17945812 - 
JAK3_12 GRCh37/hg19 chr19 17947938 17948022 - 
JAK3_3 GRCh37/hg19 chr19 17954189 17954300 - 
ALK_25 GRCh37/hg19 chr2 29432652 29432744 - 
ALK_24 GRCh37/hg19 chr2 29436850 29436947 - 
ALK_23 GRCh37/hg19 chr2 29443572 29443701 - 
ALK_22 GRCh37/hg19 chr2 29445210 29445274 - 
ALK_21 GRCh37/hg19 chr2 29445383 29445473 - 
IDH1_4 GRCh37/hg19 chr2 209113093 209113384 - 
HER4_23 GRCh37/hg19 chr2 212288880 212289026 - 
HER4_15 GRCh37/hg19 chr2 212530048 212530202 - 
HER4_9 GRCh37/hg19 chr2 212576775 212576901 - 
HER4_8 GRCh37/hg19 chr2 212578260 212578373 - 
HER4_7 GRCh37/hg19 chr2 212587118 212587259 - 
HER4_6 GRCh37/hg19 chr2 212589801 212589919 - 
HER4_4 GRCh37/hg19 chr2 212652750 212652884 - 
HER4_3 GRCh37/hg19 chr2 212812155 212812341 - 
SRC_14 GRCh37/hg19 chr20 36031574 36031813 + 
GNAS_8 GRCh37/hg19 chr20 57484405 57484478 + 
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GNAS_9 GRCh37/hg19 chr20 57484576 57484634 + 
SMARCB1_2 GRCh37/hg19 chr22 24133943 24134081 + 
SMARCB1_4 GRCh37/hg19 chr22 24143131 24143268 + 
SMARCB1_5 GRCh37/hg19 chr22 24145482 24145609 + 
SMARCB1_9 GRCh37/hg19 chr22 24176328 24176387 + 
MLH1_12 GRCh37/hg19 chr3 37067128 37067498 + 
CTNNB1_3 GRCh37/hg19 chr3 41266017 41266244 + 
PIK3CA_1 GRCh37/hg19 chr3 178916612 178916965 + 
PIK3CA_2 GRCh37/hg19 chr3 178917478 178917687 + 
PIK3CA_4 GRCh37/hg19 chr3 178921332 178921577 + 
PIK3CA_6 GRCh37/hg19 chr3 178927383 178927488 + 
PIK3CA_7 GRCh37/hg19 chr3 178927974 178928126 + 
PIK3CA_9 GRCh37/hg19 chr3 178935998 178936122 + 
PIK3CA_13 GRCh37/hg19 chr3 178938774 178938945 + 
PIK3CA_18 GRCh37/hg19 chr3 178947792 178947909 + 
PIK3CA_20 GRCh37/hg19 chr3 178951882 178952161 + 
FGFR3_7 GRCh37/hg19 chr4 1803562 1803752 + 
FGFR3_9 GRCh37/hg19 chr4 1806057 1806247 + 
FGFR3_14 GRCh37/hg19 chr4 1807778 1807900 + 
FGFR3_16 GRCh37/hg19 chr4 1808273 1808410 + 
FGFR3_18 GRCh37/hg19 chr4 1808843 1809022 + 
PDGFRA_10 GRCh37/hg19 chr4 55139704 55139897 + 
PDGFRA_12 GRCh37/hg19 chr4 55141008 55141140 + 
PDGFRA_13 GRCh37/hg19 chr4 55143555 55143659 + 
PDGFRA_14 GRCh37/hg19 chr4 55144063 55144173 + 
PDGFRA_15 GRCh37/hg19 chr4 55144529 55144682 + 
PDGFRA_18 GRCh37/hg19 chr4 55152038 55152100 + 
KIT_2 GRCh37/hg19 chr4 55561678 55561947 + 
KIT_9 GRCh37/hg19 chr4 55592023 55592216 + 
KIT_10 GRCh37/hg19 chr4 55593384 55593490 + 
KIT_11 GRCh37/hg19 chr4 55593585 55593710 + 
KIT_13 GRCh37/hg19 chr4 55594177 55594287 + 
KIT_14 GRCh37/hg19 chr4 55595501 55595651 + 
KIT_15 GRCh37/hg19 chr4 55597494 55597585 + 
KIT_17 GRCh37/hg19 chr4 55599236 55599358 + 
KIT_18 GRCh37/hg19 chr4 55602664 55602775 + 
KDR_30 GRCh37/hg19 chr4 55946091 55946330 - 
KDR_27 GRCh37/hg19 chr4 55953774 55953925 - 
KDR_26 GRCh37/hg19 chr4 55955035 55955140 - 
KDR_21 GRCh37/hg19 chr4 55960969 55961122 - 
KDR_19 GRCh37/hg19 chr4 55962396 55962509 - 
KDR_11 GRCh37/hg19 chr4 55972854 55972977 - 
KDR_7 GRCh37/hg19 chr4 55979471 55979648 - 
KDR_6 GRCh37/hg19 chr4 55980293 55980432 - 
FBXW7_11 GRCh37/hg19 chr4 153245336 153245546 - 
FBXW7_10 GRCh37/hg19 chr4 153247158 153247383 - 
FBXW7_9 GRCh37/hg19 chr4 153249360 153249541 - 
FBXW7_8 GRCh37/hg19 chr4 153250824 153250937 - 
FBXW7_5 GRCh37/hg19 chr4 153258954 153259088 - 
APC_15_HSPT GRCh37/hg19 chr5 112173872 112176035 + 
CSF1R_22 GRCh37/hg19 chr5 149433608 149433787 - 
CSF1R_7 GRCh37/hg19 chr5 149452864 149453056 - 
NPM1_11 GRCh37/hg19 chr5 170837531 170837590 + 
EGFR_3 GRCh37/hg19 chr7 55210998 55211181 + 
EGFR_7 GRCh37/hg19 chr7 55221704 55221845 + 
EGFR_15 GRCh37/hg19 chr7 55232973 55233130 + 
28 
 
GENE-EXON Reference Chromosome CHR_Start CHR_End STRAND 
EGFR_17 GRCh37/hg19 chr7 55240676 55240817 + 
EGFR_18 GRCh37/hg19 chr7 55241614 55241736 + 
EGFR_19 GRCh37/hg19 chr7 55242436 55242485 + 
EGFR_20 GRCh37/hg19 chr7 55248986 55249171 + 
EGFR_21 GRCh37/hg19 chr7 55259412 55259567 + 
EGFR_22 GRCh37/hg19 chr7 55260459 55260534 + 
MET_2 GRCh37/hg19 chr7 116339125 116340338 + 
MET_11 GRCh37/hg19 chr7 116403104 116403322 + 
MET_14 GRCh37/hg19 chr7 116411903 116412043 + 
MET_15 GRCh37/hg19 chr7 116414935 116415165 + 
MET_16 GRCh37/hg19 chr7 116417443 116417523 + 
MET_17 GRCh37/hg19 chr7 116418830 116419011 + 
MET_18 GRCh37/hg19 chr7 116422042 116422151 + 
MET_19 GRCh37/hg19 chr7 116423358 116423523 + 
SMO_3 GRCh37/hg19 chr7 128845044 128845253 + 
SMO_5 GRCh37/hg19 chr7 128845991 128846210 + 
SMO_6 GRCh37/hg19 chr7 128846305 128846428 + 
SMO_9 GRCh37/hg19 chr7 128850204 128850389 + 
SMO_11 GRCh37/hg19 chr7 128851477 128851611 + 
BRAF_15 GRCh37/hg19 chr7 140453075 140453193 - 
BRAF_11 GRCh37/hg19 chr7 140481376 140481493 - 
EZH2_15 GRCh37/hg19 chr7 148508717 148508812 - 
FGFR1_16 GRCh37/hg19 chr8 38271670 38271807 - 
FGFR1_15 GRCh37/hg19 chr8 38272077 38272147 - 
FGFR1_14 GRCh37/hg19 chr8 38272297 38272419 - 
FGFR1_13 GRCh37/hg19 chr8 38273388 38273578 - 
FGFR1_12 GRCh37/hg19 chr8 38274824 38274934 - 
FGFR1_11 GRCh37/hg19 chr8 38275388 38275509 - 
FGFR1_10 GRCh37/hg19 chr8 38275746 38275891 - 
FGFR1_9 GRCh37/hg19 chr8 38277051 38277253 - 
FGFR1_7 GRCh37/hg19 chr8 38282027 38282217 - 
FGFR1_4 GRCh37/hg19 chr8 38285864 38285953 - 
TACC1_5 GRCh37/hg19 chr8 38684686 38684893 + 
TACC1_10 GRCh37/hg19 chr8 38699805 38699965 + 
TACC1_11 GRCh37/hg19 chr8 38700807 38700913 + 
JAK2_14 GRCh37/hg19 chr9 5073698 5073785 + 
CDKN2A_2 GRCh37/hg19 chr9 21970901 21971207 - 
GNAQ_5 GRCh37/hg19 chr9 80409379 80409508 - 
GNAQ_4 GRCh37/hg19 chr9 80412436 80412564 - 
PPP6C_8 GRCh37/hg19 chr9 127911960 127912200 - 
PPP6C_7 GRCh37/hg19 chr9 127915812 127916021 - 
PPP6C_6 GRCh37/hg19 chr9 127916185 127916264 - 
PPP6C_5 GRCh37/hg19 chr9 127920520 127920661 - 
PPP6C_4 GRCh37/hg19 chr9 127923120 127923185 - 
ABL1_4 GRCh37/hg19 chr9 133738150 133738422 + 
ABL1_5 GRCh37/hg19 chr9 133747516 133747600 + 
ABL1_6 GRCh37/hg19 chr9 133748247 133748424 + 
ABL1_7 GRCh37/hg19 chr9 133750255 133750439 + 
NOTCH1_34 GRCh37/hg19 chr9 139390570 139392010 - 
NOTCH1_27 GRCh37/hg19 chr9 139397634 139397782 - 
NOTCH1_26 GRCh37/hg19 chr9 139399125 139399556 - 
EGFR_1 GRCh37/hg19 chr7 55086948 55087058 + 
EGFR_2 GRCh37/hg19 chr7 55209979 55210130 + 
EGFR_3 GRCh37/hg19 chr7 55210998 55211181 + 
EGFR_4 GRCh37/hg19 chr7 55214299 55214433 + 
EGFR_5 GRCh37/hg19 chr7 55218987 55219055 + 
29 
 
GENE-EXON Reference Chromosome CHR_Start CHR_End STRAND 
EGFR_6 GRCh37/hg19 chr7 55220239 55220357 + 
EGFR_7 GRCh37/hg19 chr7 55221704 55221845 + 
EGFR_8 GRCh37/hg19 chr7 55223523 55223639 + 
EGFR_9 GRCh37/hg19 chr7 55224226 55224352 + 
EGFR_10 GRCh37/hg19 chr7 55224452 55224525 + 
EGFR_11 GRCh37/hg19 chr7 55225356 55225446 + 
EGFR_12 GRCh37/hg19 chr7 55227832 55228031 + 
EGFR_13 GRCh37/hg19 chr7 55229192 55229324 + 






Supplementary Table S2. Summary of molecular data from the ISH and sequencing analyses 
conducted on both the pre-treatment primary tumor and the liver biopsy obtained after progression 
on panitumumab plus vemurafenib treatment. List of abbreviations: IHC, immunohistochemistry; 
ND, not done; SISH, dual-color silver in-situ hybridization; FISH, fluorescence in-situ 
hybridization. 
 Pre-treatment tumor sample Post-treatment tumor sample 
MET IHC H-score 150 H-score 270 
MET SISH 18% amplified cells  85% amplified cells 
MET FISH 16% amplified cells 75% amplified cells 
HER-2 IHC & SISH Negative Negative 
Next-generation sequencing* 
 
BRAF V600E  
(allelic frequency 27%) 
SDHD I40V  
(allelic frequency 44%) 
BRAF V600E  
(allelic frequency 14%) 
SDHD I40V 
(allelic frequency 57%) 
No additional mutations 
 
 
*Based on the percentage of mutant reads, both pre-treatment and post-treatment tissue samples 
displayed substantially comparable tumor purity. 
  
